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General introduction
General introduction
The human immune system constitutes a line of defense against both external and 
internal threats that ultimately compromise homeostasis. However, with the 
increasing specialization and regulation of the immune system the chance of error 
increases, resulting in failing clearance of pathogens or tumors and giving rise to 
autoimmunity. To minimize the risks of autoimmunity, compartments fundamental to 
survival and reproduction like brain, eyes, testis and uterus show immunological 
adaptations to prevent tissue damage. Engraftment of these so-called immune 
privileged sites does not result in the induction of graft rejection or fetal loss. Immune 
privileged sites share one or more unique features like tissue expression of Fas 
ligand, absence of lymphatic vessels, reduced levels of major histocompatibility 
complex (MHC) class I antigens, absence of MHC class II antigens and abundant 
expression of cytokines. Immune privilege ofthe eye is particular well studied in mice 
[1]. It was shown that after injection of allogeneic DBA/2 cells in the anterior 
chamber, mice lost the ability to reject DBA/2 skin grafts demonstrating a deviant 
immune response termed anterior chamber associated immune deviation (ACAID). 
Here, upon injection of the antigen, ocular antigen presenting cells that have come 
under the influence of the immunomodulatory intraocular environment, migrate to the 
spleen where they create an immunosuppressive microenvironment through the 
production of chemoattractants and cytokines like TGF-ß and thrombospondin-1. 
The net result is the induction of regulatory T cells. In analogy to this ACAID model, 
tolerance induction at the feto-maternal interface during pregnancy might well be an 
active process constituted under the influence of local cytokines that are induced by 
a distinct pattern of MHC class I expression and mediated through a skewed 
population of immune competent cells.
The role oftrophoblast cells in the biology of placentation
The mammalian concept of viviparity comprises a great challenge for maternal 
physiology, including adaptations of the endocrine, vascular and immune systems. 
Notwithstanding its universal application in mammals, the functional and biological 
details of placentation are very diverse, presumably to suit different reproductive 
strategies such as numbers of fetus and gestational length. In human placentation 
the placental side of the interface deeply invades the maternal part. The basal 
membrane integrity is lost, resulting in synchysis of the interface and full contact of 
both cell populations. In this process the maternal blood flow is diverted through the 
intervillous space, thus constituting a haemochorial placentation.
The human reproductive effort is directed to a single sibling. As the rate of abnormal 
embryos is relatively high, it is likely that a system is implicated that triggers 
implantation failure [2]. This is supported by an estimated frequency of spontaneous 
loss of up to 60%, half ofwhich occur before clinical detection of pregnancy [3]. 
Implantation occurs six or seven days after conception. After entering the uterine 
cavity the zona detaches from the blastocyst exposing its outer cover of 
multinucleated trophoblast cells. The blastocyst adheres to the uterine epithelium. In 
this process microvilli on the surface of the trophoblast cells interdigitate with 
pinopodes on the uterine epithelium. Trophoblast cells will upon contact, decidualise 
the endometrium. The blastocyst becomes embedded by the decidualised stroma. 
Columns of cytotrophoblast cells emerge from the blastocyst, forming tree like 
structures called villi. By week 10 of pregnancy the oxygen consumption increases 
creating a short period of local hypoxia followed by a diversion of the maternal blood
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flow through the inter villous space and thus constituting the haemochorial placenta. 
The majority of the villi float freely in the inter villous space and play a role in the 
exchange of nutrients. The throphoblast stem cell resides in the villi and is called 
(villous) cytotrophoblast [4]. Villous cytotrophoblast can be observed during early 
pregnancy as a confluent inner layer of cells lining the villous epithelium consisting of 
syncytiotrophoblast cells (Figure 1).
Figure 1: Haemochorial placentation and organization oftrophoblast populations
sa: spiral artery, db: decidua basalis, ivs: intervillous space, cv: chorionic villi, st: syncytio­
trophoblast, vet: villous-cyto-trophoblast, mvc: mesenchymic-villous-core, ec: endothelial cell, 
upsa: uncoiling process of the spiral arteries, evct p: proliferating extra-villous-trophoblast 
cells (=cell column), evct i: invading extra-villous-trophoblast cells. Adapted from Blaschitz et 
al [4].
A small part of the villi are anchored to the decidua. At the tip of these anchoring villi 
a cell column of proliferating cytotrophoblast cells disrupts the epithelial 
syncytiotrophoblast layer. From those columns of extra-villous cytotrophoblast a 
second wave of trophoblast cells deeply invades the decidua and differentiate into 
distinct populations of extra-villous trophoblast cells. The intra-mural, endovascular 
and interstitial trophoblast respectively invade the arterial walls, arterial lumen and 
interstitium. Intra-mural trophoblast cells change the endothelial design in such a way 
that its vaso-constrictive properties are lost, resulting in large low impedance vessels 
and an increase of the utero-placental blood flow. In this way the feto-placental unit 
is ensured of an ample supply of nutrients needed for its growth. Finally, in the inner 
third of the myometrium interstitial trophoblast invasion is halted and trophoblast cells 
differentiate into multi nucleate placental bed giant cells. Towards third trimester 
pregnancy the inner layer of villous cytotrophoblast cells gradually disappears. 
Trophoblast invasion needs to be strictly regulated and numerous factors have been 
proposed to be crucial for implantation. Promising candidates are depicted in Table
10
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1. Many of these factors can directly or indirectly be related to immune competent 
cells and stress the importance of immune adaptation.
Table 1: Factors involved in implantation
Factor ligand/target ref
pinopodes microvilli affected by progesterone
Hormones progesterone
Cell adhesion molecules MUC-1 [5]
Integrins fibronectin,
laminin,
collagen
trophinin/tastin
growth factors EGF EGF-R
CSF-1 CFS-1-R
LIF
IL-1 IL1-R tI affects integrins
calcitonin affected by progesterone
HOXA-10 affected by progesterone
COX-2 rate limiting enzyme in
prostaglandin synthesis
MMP extracellular matrix proteolisis
matrix
TIMP TIMP-3 MMPs limits trophoblast invasion
extra cellular matrix fibronectin, inhibits trophoblast
proteins laminin, invasion, prolactin and
collagen IGFBP-1 production
IGFBP-1 IGF-II inhibition of IGF-II, inhibit [6]
trophoblast invasion
oxygen tension balance between
trophoblast proliferation
and differentiation
Immunologic see table 2
Reviewed by Giudice et al. [7]
Norwitz et al. [8]
Nikas [9]
Cross et al. [10]
Fisher & Damsky [11 ]
MUC-1: mucine-1, EGF(-R): epidermal growth factor(-receptor), CSF-I(-R): macrophage colony 
stimulating factor(-receptor), LIF(-Rtl): leukemia inhibitory factor(-receptor), HOXA-10: homeobox 
gene, COX-2: cyclooxygenase, Mm P: matrix metalloproteinase, TIMP: tissue inhibitor of metallo 
proteinase, IGF-II: insulin like growth factor, IGFBP-1: IGF binding protein
Pregnancy disorders
Although disorders of pregnancy like recurrent miscarriage and preeclampsia are 
relatively common and easily diagnosed, the underlying pathophysiological 
mechanisms remain fairly unresolved. About 12% to 15% of clinically recognizable 
pregnancies result in spontaneous miscarriage. It is estimated that 60% of embryos 
are lost before clinical detection of pregnancy, half of which represent implantation 
failure. Recurrent early pregnancy loss is being defined as two or three, or more 
consecutive miscarriages, affecting 0.5-2.0% of reproducing couples [3]. Different 
causes have been proposed for recurrent miscarriage (reviewed by Regan [3]). A
11
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genetic contribution is suspected in recurrent miscarriage as a family history of 
recurrent miscarriage poses an increased risk. Fetal chromosomal abnormalities 
account for 50% of spontaneous losses. In recurrent miscarriage chromosomal 
defects caused by parental translocation or de novo mutations are likely to contribute
[12]. Reports of endocrine abnormalities have focussed on luteal function, as a role 
for an aberrant timing of implantation in relation to the responding corpus luteum has 
been suggested. However, some 80% of recurrent miscarriages cannot be 
accounted for by chromosomal defects or hormonal disorders.
Preeclampsia is a disorder that evolves during second or third trimester pregnancy 
with various clinical symptoms and is a major cause of maternal and perinatal 
morbidity and mortality [13]. Key features of preeclampsia are maternal hypertension 
in combination with proteinuria. The syndrome haemolysis, elevated liver enzymes 
and low platelet count (HELLP) can be regarded as a further complication of 
preeclampsia although this may also represent a separate pathology as indicated by 
a difference in the expression of proteolitic factors in HELLP and preeclampsia [14] 
[15]. It is estimated that 6-20% of all pregnancies are affected by some sort of 
hypertension of which one third will progress to preeclampsia or HELLP syndrome
[13]. Pregnancy related hypertension putatively results from poor placental perfusion 
that is compensated for by an increase in maternal blood pressure. In preeclampsia 
systemic endothelial cell dysfunction develops such as in the kidney, liver and brain. 
Therefore women at risk for endothelial damage and dysfunction (i.e. diabetes, 
hyper-cholesterolemia, hyper-homocysteinemia) are particular prone to 
preeclampsia. Although preeclampsia symptoms become apparent during the 
second or third trimester, histological studies show an altered placental morphology 
that originates during early pregnancy [16,17].
As the risk of recurrent spontaneous miscarriage increases with each subsequent 
pregnancy loss and the risk of preeclampsia decreases for each consecutive 
pregnancy, it seems plausible that this is the consequence of (mal) adaptation of the 
human body upon recognition of a preceding pregnancy. The human immune system 
is capable of such adaptation through mechanisms like skewing of effector cell 
repertoire and build up of memory populations. Therefore disorders like recurrent 
miscarriage and preeclampsia might have an immunological background. Positive 
recognition rather than masking of the fetal allo (paternal)-antigens is thought to be 
essential for successful pregnancy.
Common denominator in recurrent miscarriage, and preeclampsia is thought to be 
aberrant implantation, occurring during early pregnancy due to abnormal behavior of 
trophoblast cells. It is suggested that this is related to preimplantational differences in 
leukocyte populations [18].
Resolving the primary causes of preeclampsia is greatly held back by the fact that 
most observations for obvious reasons involve early third trimester or near term 
placental tissue. Factors that can affect the first wave of trophoblast invasion and 
thus implantation can be, cytokines, autoantibodies, extra cellular matrixproteins and 
surface antigens.
In women with a history of recurrent miscarriage defective placentation was reported 
[19]. In particular aberrant depth of trophoblast invasion and inadequate syncytium 
formation were reported [12]. In preeclampsia it has long been evident that the 
physiological changes of the spiral arteries are mainly restricted to the decidual part 
leaving the myometrial segments unaffected [16]. Further studies show that the 
myometrial segments of the spiral arteries show disorganization and hyperplasia of 
the media whereas the decidual part shows signs of artherosis [17]. The histological
12
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data that show aberrant vessel pathophysiology are in tune with in vivo findings of 
uterine and spiral artery blood flow, showing increased vessel impedance in 
preeclampsia [20]. Concomitantly, poor perfusion in preeclampsia leads to placental 
hypoxia resulting in up regulation of oxygen tension dependent molecules like 
p R0XY-1 [21] or possibly erythropoietin (e Po ) [22].
Furthermore, in preeclampsia it is suggested that macrophages and T cells invade 
the area around these affected spiral arteries [23-25]. In vitro studies show that 
macrophages can induce trophoblast cell apoptosis when co-cultured in the 
presence of tumor necrosis factor a (TNF-a)[26]. Apoptosis of extra villous 
trophoblast cells is reported to be increased in preeclamptic placental tissue [27]. 
The expression of interleukin 1 (IL-1) and TNF-a cytokines is regulated by 
transcription elements that are highly homologous to the hypoxia responsive 
transcription element of EPO, suggesting indirect involvement of these cytokines in 
the pathology of preeclampsia. In vitro cultures of cytotrophoblast cells under hypoxic 
conditions show an increase in proliferation of these cells. In contrast, the 
invasiveness of the cytotrophoblast cells was decreased, implicating a decline in 
trophoblast differentiation [28]. Therefore a first trimester defect in trophoblast 
differentiation can hamper the second wave of trophoblast invasion, ultimately 
contributing to the etiology of subsequent preeclampsia. Insulin like growth factor 
(IGF-II) is abundantly expressed by invading trophoblast cells, enhancing in vitro 
trophoblast migration. The IGF binding protein (IGFBP-1) a product of decidua 
counteracts IGF-II. Both peripheral and local IGFBP-1 levels are decreased in 
preeclampsia [7]. A decrease in the expression of pregnancy specific glycoprotein 
(PSG) RNA and leukemia inhibitory factor (LIF) was associated with recurrent 
miscarriage [29,30]. Moreover, PSG stimulated the in vitro (IL-10) cytokine 
production by monocytes, demonstrating an indirect way to affect trophoblast 
invasion.
Recent histological data on the putative association of antiphospholipid antibodies 
with early pregnancy loss show a relation to defective endovascular trophoblast 
invasion rather than excessive intervillous thrombosis [31]. The anticardiolipin and 
antinuclear autoantibodies as detected in recurrent miscarriage are also related to 
implantation failure during in vitro fertilization procedures [32]. The association of 
recurrent miscarriage with various autoantibodies has, based on a murine model of 
spontaneous fetal loss, led to preventive measures like intravenous injection of IgG 
[33,34] and paternal leukocyte immunization [35-38]. However, the effectiveness of 
those therapies is doubtful illustrating that any extrapolation of data based on inbred 
mouse strains is very difficult [35,39]. Women affected by the autoimmune disease 
systemic lupus erythematosus (SLE) are particular prone to spontaneous abortions 
[3]. Some of the antibodies found in SLE bind to laminin.
Laminins are extracellular matrix proteins involved in implantation and an abolishing 
effect of anti laminin antibodies on in vitro trophoblast attachment was suggested 
[40]. The cell surface glycoprotein mucine (MUC-1) is expressed on human 
endometrium and has been shown to inhibit cell-cell interactions by steric hindrance 
[5]. Endometrial MUC-1 glycoprotein is reduced in recurrent miscarriage whereas in 
“healthy” receptive endometrium, MUC-1 is abundantly expressed [5].
Matrix metalloproteins are proteolytic factors involved in trophoblast invasion; in 
preeclampsia expression of MMP seems shifted as compared to normal pregnancy 
and pregnancies complicated by HELLP [41,42]. Integrins are adhesion molecules 
present in decidual and extra-villous trophoblast cells. In normal pregnancy a switch 
in integrin expression can be observed during the differentiation of trophoblast cells
13
Chapter 1
[43]. This integrin switch is incomplete in preeclampsia [44,45]. In recurrent 
miscarriage the expression of intercellular adhesion molecule 1 (ICa M-1, involved in 
antigen non-specific intercellular adhesion via leukocyte functional antigen (LFA)) in 
endovascular trophoblast was reported whereas expression in normal pregnancies 
was absent [24]. In recurrent miscarriage couples, sharing of class II has been 
suggested [46]. In particular increased sharing of the HLA-DQA1 in couples with 
recurrent miscarriage coupled and the suggested deficit in offspring homozygous for 
this allele [47,48].
The incidence of preeclampsia seems to be associated with new paternity, duration 
of sexual cohabitation and use of barrier contraceptives [13]. Therefore, different 
aspects of exposure to paternal antigens seem to play a role in the pathophysiology 
of preeclampsia.
In preeclampsia the placental expression of the non-classical HLA class I molecule 
HLA-G seems decreased, whether this decrease is unrelated to reduced numbers of 
trophoblasts in preeclampsia needs to be resolved [49-51]. In cultures, cells from 
preeclamptic placentas failed to up regulate HLA-G expression and properly 
modulate their integrin and MMP-9 expression [45].
In conclusion, in recurrent miscarriage and preeclampsia different aspects of 
implantation are altered. It is suggested that immune competent cells play a role in 
regulating this process of trophoblast invasion and are involved in disturbed placental 
development in early pregnancy.
Immunological aspects of pregnancy
The placenta and chorionic membranes form an interface between the developing 
fetus and the maternal body. In the 1950’s Medawar postulated his paradigm of the 
fetal allograft. In answer to this paradigm Medawar proposed three solutions being 
anatomical feto-maternal separation, fetal antigenic immaturity and maternal 
immunological inertness [52]. Although, in those days maternal immunization in 
hemolytic disease of the newborn focused on red cell antigens, Medawar already 
implicated a role for “ordinary tissue antigens” and stressed the importance of 
anatomical feto-maternal separation. In the last two decades it has become evident 
that fetal and maternal cells are exchanged in both directions [53,54] and that fetal 
antigens are expressed [55-58]. Moreover, in a murine model it was shown that fetal 
cells were cleared from the mother and that clearance depended on the allogenicity 
of the fetal cells being mediated by the immune system [53]. The local maternal 
immune system therefore encounters the dilemma of permitting and facilitating 
implantation and placentation of the semi-allogeneic fetus whilst remaining on the 
alert for pathogens. Therefore, some form of maternal tolerization is implicated.
Based on murine models it was proposed that maternal tolerance to the fetal 
alloantigens and thus successful pregnancy is dependent on T helper 2 (Th2) 
cytokines that counteract T helper 1 (Th1) cytokines [59]. In this concept cytokines 
are divided in Th1 (i.e.IL2, IFN-y, TNFa) and Th2 (i.e. IL4, IL10,) cytokines. However, 
recent data on the expression of various cytokines at the fetal maternal interface 
show a complex system that cannot be covered by the Th1/Th2 paradigm only [60]. 
In analogy, in the “danger model” proposed by Matzinger, the induction of tolerance 
is related to activation of T cells through the T cell receptor complex (signal 1) in the 
absence of co-stimulation (signal 2), as a result of presentation of antigen by 
immature dendritic cells or non-professional antigen presenting cells, switching the 
class of response rather than shifting Th1/Th2 cytokines alone [61].
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Several immunological factors have been proposed that can affect different stages of 
pregnancy (Table 2). During the menstrual cycle the endometrium becomes 
receptive for a consecutive implantation, implicating extensive changes of this 
uterine epithelium. During the late luteal phase the local uterine lymphocyte 
population skews towards a population of predominantly Natural Killer (NK) cells and 
to a lesser extent T cells, B cells and monocytes.
Recent studies show that trophoblast cells not only shield but also play a role in 
modulation of the maternal immune competent cells by expressing a distinct profile 
of human leukocyte antigens (HLA). Trophoblast cells are known to predominantly 
express the HLA-G, C and E molecules [56,57], whereas class I HLA-A, HLA-B and 
class II HLA-DQ, HLA-DR molecules seem absent. The HLA molecules play a major
Table 2: Immunologic factors that putatively affect implantation
factor target/function ref
HLA clasl HLA-G NK cells O’Brien et al. [67]
HLA-C NK,T cells
HLA-E NK cells
HLA- classll peptide presentation to T cells Mellor & Munn [68]
HLA classili complement kill of pathogens/allogeneic cells Xu et al. [69]
cytokines lL-10 Th2 cytokine, upregulation HLA-G Chaouat et al. [60]
down regulation class la Moreau et al. [70]
lL-4 Th2 cytokine
lL-2 Th1 cytokine
IFN-y Th1 cytokine
tryptophan suppression of T cell activity Munn et al. [71]
pathogens HCMV Fisher et al. [72]
US2 class l heavy chain degradation
US3 class l accumulation in the ER Jun et al. [73]
US6 peptide loading
US11 class l heavy chain degradation
HSV Schust et al. [74]
ICP47 peptide loading
Fas-ligand induction of apoptosis Hammer & Dohr [75]
Reviewed by Loke & King [76]
Johnnson et al. [77]
Mellor & Munn [68]
Saito [78]
Jerzak & Bischof [79]
HLA: human leukocyte antigen, IL: interleukin, IFN-y: interferon y Th: T helper, HCMV: human 
cytomegalovirus, US(2,3,6,11): HCMV encoded proteins, HSV: herpes simplex virus, ICP47: HSV 
encoded protein
role in recognition of antigens and regulate cellular and humoral immunity. Since the 
fetus is semi-allogeneic to the mother and it has conclusively been shown that both 
fetal cells and placental tissues do express the paternally derived and thus foreign 
HLA antigens [62-64], it can be assumed that every successful pregnancy must be 
accompanied by redirection of maternal immune competent cells like Natural Killer 
(NK) cells, T cells and B cells. Of particular interest is the role of NK cells. During 
early pregnancy the so-called large granular lymphocytes or uterine NK cells (in 
analogy to peripheral NK cells), form the major population of immune competent
15
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cells at the interface with the placenta [65]. Uterine NK cells carry receptors for HLA 
antigens and are potent producers of a wide variety of cytokines, whereas 
trophoblast cells carry receptors for cytokines [66]. In this way HLA-G expression by 
trophoblast cells may shift the cytokine production by NK cells in such a way as to 
create an environment that regulates immune activation (hence the need for 
suppression is obliterated) and facilitates trophoblast invasion.
Together this suggests that the interaction of HLA antigens with in particular NK cells 
at the placental interface could be critical in determining the outcome of pregnancy.
Natural Killer cells
NK cells are involved in the innate immune response, in particular in killing of tumor 
or virally infected cells and in pregnancy. NK cells spare cells that express adequate 
amounts of MHC class I molecules whereas transformed cells that have lowered or 
aberrant MHC class I expression are killed [80].
NK cells are characterised by the expression of the neural cell adhesion molecule 
(CD56) and the concurrent absence of T cell receptor molecules (CD3). Involvement 
of the CD56 antigen as an adhesion molecule in NK/target cell interaction has been 
suggested. Subsets of NK cells co-express the low affinity receptor FcyRIII (CD16). 
Based on these two surface antigens distinct populations of NK cells can be 
distinguished being CD56bri9htCD16(ne9°rdim) or CD56dimCD16pos cells.
NK cells comprise up to 15% of all peripheral blood lymphocytes, whereas the uterus 
comprises a second major population of NK cells embedded in the uterine epithelium 
accounting for up to 70% of local lymphocytes. Strikingly, 90% of peripheral NK cells 
are CD56dimCD16pos cells whereas the majority of the uterine NK cells have the 
CD56bri9htCD16ne9 phenotype. The remaining 10% of peripheral NK cells also have 
this CD56bri9htCD16ne9 phenotype although they do not display the characteristic 
granules found in uterine NK cells. Less than 4% of decidual NK cells have the 
CD16pos phenotype [81]. It remains unresolved whether these uterine NK cells are 
derived from the peripheral NK cell population or mature in situ from a bone marrow 
derived progenitor cell. It is suggested that migration of decidual NK cells and 
monocytes to the feto-maternal interface is regulated through expression of 
monocyte inflammatory protein (MIP-1a) by trophoblast cells [82]. Furthermore, 
expression of very late antigen (VLA-1, CD49a) by decidual NK cells, not peripheral 
NK cells, can implicate a homing function for this antigen [81]. VLA-1 is an adhesion 
molecule that belongs to the integrin family and binds to collagen and laminin. 
Whereas decidual NK cells do not express mature T cell markers (i.e. CD3, CD5 and 
CD6), the majority does express early T cell antigens like CD2 and CD7, suggesting 
a common origin [66].
NK cells putatively originate from a common NK or T/B lineage progenitor cell. 
Development of this CD34posCD56ne9 progenitor takes place in the microenvironment 
of the bone marrow under the influence of IL-15 [83]. Binding of the receptor tyrosine 
kinases Flt3 and c-kit with their ligands results in upregulation of the IL-15 receptor 
complex on the progenitor cells. Differentiation of progenitor cells starts upon 
induction with bone marrow derived IL-15 resulting in mature NK cells that have the 
CD56bri9ht phenotype. For further maturation, induction of these “mature” NK cells 
with IL-12 and/or IL-18 is needed for fully functioning NK cells with the capacity to 
produce IFN-y and to kill [84]. Recently it has been shown that incubation of bone 
marrow derived progenitor cells with the combination of IL-15 and IL-21 cytokines 
results in CD56dimCD16pos NK cells. It is suggested that the expression of MHC class
16
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I molecules affect the maturation ofthe CD56dim NK subset, whereas the contact with 
bone marrow stromal cells is required for the acquisition of NK receptors [83].
Table 3: Expression of human NK cell antigens in the CD56briJht and CD56dim NK cell 
subsets (adapted from Cooper et al [83]).
peripheral Blood endometrial/
decidual
remarks on function ref
¿z.
.q
65DC CD56d'm CD56br'ght uNK
common NK
antigens
CD56 ++ + ++ unknown
CD16 -/+ ++ - ADCC
CD57 + + - [66]
granules -/+ ++ +++ (some - ) cytolytic
NK receptors
KIR -/+ ++ ++ [85]
CD94 ++ -/+ +++ inhibition via HLA-E [86]
NKG2A + -/+ +++ inhibition via HLA-E [57]
LIR-1 ILT2 - + +
p49 - - + [87]
VLA-1 - - ++ [81]
cytokine receptors +
IL-2Raßy + - p75 55 activation
IL-2Rßy + + activation
c-kit + -
IL-1RAcP + +
IL-1RI + - +
IL-18R + - +
CCR7 ++ - T cell homing
CXCR3 + - +
CXCR1 - ++
CX3CR1 - ++
adhesion molecules +
CD2 ++ + +
L-selectin (CD62L) ++ - + vascular interaction
PEN5-PSGL-1 - + binding to CD62L
LFA-1 + ++
CD44 ++ +
CD49 ++ +
Subdivision of peripheral NK cells in CD56briJht and CD56dim subsets shows distinct 
functional and phenotypic properties forthese subsets (Table 3)[83]. CD56briJht cells 
combine poor cytotoxic reactivity with strong production of immunoregulatory 
cytokines (i.e. IFN-y, TNF-ß, IL-10, IL-13, GM-CSF), whereas CD56dimCD16pos NK 
cells show strong cytotoxic reactivity and antibody dependent cytotoxicity mediated 
via CD16 but negligible production of cytokines. However in vitro stimulation of 
CD56briJht NK cells with IL-2 or IL-12 raises the level of cytotoxicity to that of CD56dim 
cells. Furthermore, the proliferation of CD56bn9ht cells can be induced by minute 
quantities of IL-2 or IL-15, whereas CD56dimCD16pos show relatively low proliferative 
capacity. Based on this deficient proliferative response and cytokine production it is
17
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suggested that the CD56dimCD16pos NK cells represents a more terminally 
differentiated subset than CD56briJht cells. Interestingly, CD56dlmCD16pos NK cells 
cultured in the presence of IL-2 or IL-15 increase surface expression of CD56, 
whereas expression ofCD16 is unaffected.
Table 4: Human NK cell receptors and co-receptors involved in the regulation of NK 
mediated functions (adapted from Biassoni et al [97]).
gene name chromosom receptor name function Ligand specificity (receptor)
HLA specific receptors
KIR2DL1 19 p58.1 inhibitory HLA-Cw2, 4, 5, 6
KIR2DL2 19 p58.2 inhibitory HLA-Cw1,3,7,8
KIR3DL1 19 p70 inhibitory HLA-Bw4
KIR3DL2 19 p140 inhibitory HLA-A3, -A11
KIR2DL4 19 p49 inhibitory? HLA-G
LIR1/ILT2 19 LIR1/ILT2 inhibitory HLA-G, broad HLA class I 
specificity
LIR2/ILT4 19 LIR2/ILT4 inhibitory? HLA-F
CD94 12 a a a
NKG2A 12 CD94 NKG2A inhibitory HLA-E
KIR2DS1 19 p50.1 activating HLA-Cw2, 4, 5, 6
KIR2DS2 19 p50.2 activating HLA-Cw1,3,7,8
KIR2DS4 19 p50.3 activating unknown
NKG2C 12 CD94/NKG2C activating HLA-E
reviewed by Boreggo et al [98]
non HLAspecific receptors
LAIR1 19 p40 LAIR1 inhibitory unknown
IRC1 17 IRp60 inhibitory unknown
CMRF35 19 CMRF35 ? unknown
AIRM1 19 p75/AIRM1 inhibitory unknown
NKp46 19 NKp46 activating unknown
1C7INK-A1 6 NKp30 activating unknown
NKp44 6 NKp44 activating unknown
NKG2D 12 NKG2D activating MICA, MICB, ULBP
2B4 1 2B4 activating CD48
KLRF1 12 NKp80 activating unknown
a Forms heterodimers with different members of the NKG2 family.
NK cells have receptors with known specificity for MHC class I molecules and the 
number of these receptors reported is still increasing (Table 4). Furthermore, recently 
a new group of receptors has been identified that is involved in the regulation of n K 
mediated cytotoxicity upon recognition of non-HLA ligands. NK cell receptors can 
either be activating or inhibitory and distribution of NK cell receptors is 
heterogeneous, therefore a distinct NK cell does not necessarily express all 
receptors that can be found in an individual. The KIR2DL4 killer immunoglobulin like 
receptor (KIR) and immunoglobulin like transcript 2 (ILT2) are so far the only known 
representatives of these two groups of NK receptors specific for HLA-G [88-90]. KIR 
and ILT2 expression is far more abundant in CD56dimCD16pos than in CD56bnjht NK
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cells, the latter also being reported as KIR and ILT2 negative [66,85,91]. This is in 
contrast to decidual CD56bn 9ht NK cells that do express KIR with an intensity that is 
stronger than that found in CD56dim cells [85]. Interestingly, bright expression of 
KIR3DL1 cells was limited to decidual CD56 im Nk  cells. In contrast, the heterodimer 
CD94/ NKG2A receptor, member of a third group of NK receptors of the C-type lectin 
family and ligand for HLA-E, is highly expressed by both peripheral and decidual 
CD56bri9ht NK subset [57,85,92-94]. Expression of Kir  andILT2 receptor has also 
been observed in T cells [95] [85,96].
NK cells in non-pregnant endometrium
Endometrial NK cells represent a distinct population of NK cells that predominantly 
have the CD56briJht phenotype and account for +/- 70% of local lymphocytes. The 
menstrual cycle can be divided in the proliferative phase and secretory phase during 
which the uterine epithelium is transformed to become receptive for subsequent 
implantation. During these stages of the menstrual cycle endometrial lymphocyte 
populations and subsets show significant deviation in numbers [99]. In non-pregnant 
early proliferative endometrium T cells can be found next to CD56posCD16ne9 NK 
cells, macrophages and B cells (in decreasing order). These early proliferative phase 
endometrial NK cells show (after purification) negligible in vitro lytic activity. During 
the subsequent phases of the menstrual cycle the CD56briJht population strongly 
increases. Concurrent in vitro cytotoxic activity of purified endometrial NK cells, was 
of the same magnitude as NK cells isolated from peripheral blood [100]. In contrast 
to increasing NK cell numbers, T cell numbers decrease towards late secretory 
phase. Finally, at the late secretory phase of the menstrual cycle the total number of 
leukocytes is increased due to a rise in the proportion of CD56bri9htCD16ne9 NK cells 
[65,66,101].
In women having previously experienced recurrent miscarriage, secretory phase 
endometrial biopsies show elevated numbers of CD16pos cells and CD56pos NK cells 
and concomitant increases in CD4pos, CD14pos and class IIpos cells [102]. Women 
who experienced miscarriages in the pregnancy after the endometrial biopsy had 
more decidual CD16pos cells and CD56pos NK cells (and CD4pos, CD8pos or CD14pos 
cells) than those who had live births.
In women treated for infertility by in vitro fertilization, pre implantation endometrial NK 
cell populations were evaluated [103]. In women with failed implantation, the 
CD56dimCD16pos NK cells subset was decreased whereas women that subsequently 
aborted showed an increase in this subset and decrease in the CD56briJhtCD16ne9 
fraction.
In summary, in healthy receptive endometrium the CD56briJht NK cell population is 
increased and expression of the CD56dimCD16pos NK cells seems detrimental to 
implantation/pregnancy.
Decidual NK cells during pregnancy
During early pregnancy the numbers of endometrial NK cells (now denoted as 
decidual n K cells) further increase as compared to the different stages of the 
menstrual cycle [101]. Concurrently, the numbers of macrophages/ monocytes seem 
to increase whereas T cell numbers further decrease.[99]
The in vitro cytotoxic activity of first trimester purified decidual NK cells is similar or 
lower than that found in NK cells isolated from peripheral blood [100]. In pregnancies 
with blighted ova, the in vitro NK cytotoxic reactivity of (non-purified) decidual 
lymphocytes was increased as compared to peripheral lymphocytes in contrast to
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normal pregnancies that show the opposite with decreased decidual NK cytotoxicity 
[99]. A change in cytotoxic activity can be the consequence of a shift in expression of 
inhibitory/activating receptors in the population of NK cells. Indeed, in blighted ova 
pregnancies a decrease in the number of KIR (GL183:p58.2/p50.2) positive 
CD56briJht decidual NK cells was observed, suggesting a shift in expression of those 
KIR [104].
Decidual samples of women with recurrent pregnancy loss show a significant 
decrease in CD56pos NK cells suggestive of low absolute numbers of CD56pos cells 
as compared to normal pregnancy [105]. Concomitantly, the expression of IL2Ra 
(CD25) was increased suggesting activation of NK and T cells.
During the course of pregnancy the numbers of decidual NK cells decrease whereas 
the proportion of T cells increases. Strikingly, in preeclampsia pre term decidual 
samples show a tendency towards increased numbers of CD56pos (including both 
CD56dim and CD56briJht) NK cells [106]. This increase was more pronounced in 
preeclampsia that presented with fetal growth retardation. Whereas decidual T cell 
numbers were similar for preeclampsia and controls, the number of decidual CD8pos 
cells had increased in contrast to a decrease in decidual CD4pos T cells. These data 
suggest that a both decidual NK cells and T cells are affected in preeclampsia.
In conclusion, the decidual NK cells population seems affected under pathological 
conditions and is putatively balanced by the interactions of HLA and/or non-HLA 
specific receptors, cytokine receptors and adhesion molecules with its ligands.
Peripheral NK cells and pregnancy disorders
Peripheral blood lymphocytes consist of approximately 20% CD56dim and 1% 
CD56briJht NK cells [85]. Over 80% of peripheral blood NK collii express the CD16 
antigen [81]. Interestingly, the population of peripheral CD56briJht n K cells appeared 
elevated during early pregnancy [66,85] and some but not all pregnancies, seem 
associated with an increase in CD56pos NK cells (comprising both CD56dim and 
CD56bri9ht cells) [81].
In women treated for infertility with in vitro fertilization the peripheral NK cell 
populations and in vitro function were evaluated [103]. In women with failed 
implantation, at the day of embryo transfer the numbers of both CD56pos and 
CD56posCD16pos peripheral NK cell subsets were increased as compared to women 
in which implantation was successfully achieved. Furthermore, women in which 
implantation was successfully achieved, the peripheral NK cell cytotoxic reactivity at 
day of embryo transfer was decreased as compared to that found at the mid 
secretory phase of the cycle prior to IVF. Women that subsequently miscarried 
showed increased cytotoxic reactivity at day of embryo transfer.
In recurrent miscarriage, the preconceptional peripheral cytotoxic reactivity was 
increased as compared to levels found in normal pregnancy [107]. Although in 
recurrent miscarriage the preconceptional CD56posCD16pos seemed unaffected [108]. 
However, more recently both preconceptional cytotoxic reactivity and 
preconceptional CD56pos and CD56posCD16pos were suggested to be similar in 
recurrent miscarriage and controls ([109], this thesis). In contrast, during early 
pregnancy both cytotoxic reactivity and the CD56posCD16pos NK cell subset were 
increased in women who subsequently went on to have a miscarriage, whereas the 
CD56pos population decreased. More recently an increase in peripheral 
CD56posCD16pos NK cells in recurrent miscarriage was confirmed [110].
It has also been suggested that the presence of anti-phospholipid, anti-cardiolipin 
and anti-phosphatidylserine antibodies in recurrent miscarriage was related to
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increased preconceptional numbers of peripheral CD56pos and CD56posCD16pos NK 
cells, although antibodies to nuclear components could not be related to increased 
numbers of NK cells. During subsequent pregnancy peripheral CD56pos and 
CD56posCD16pos NK cells were increased [108]. The activation status of peripheral 
NK cells was analyzed by determining CD69 expression. All peripheral NK cell 
subsets in recurrent miscarriage and the CD56bri9ht subsets excluded in idiopathic 
infertility showed increased expression of CD69 as compared to fertile controls [111]. 
Interestingly, the expression of CD94 on peripheral CD56dim NK cells, but not on 
CD56bri9ht Nk  cells, was decreased in recurrent miscarriage and idiopathic infertility 
as compared to fertile controls.
Taken together we suggest in recurrent miscarriage an increase of peripheral 
CD56posCD16pos NK cells and concomitant increase in peripheral NK cell cytotoxic 
reactivity.
It has been suggested that in recurrent miscarriage also peripheral T cells were 
affected. An increase in peripheral T cells (CD4pos and CD25posCD3pos, 
CD25posCD4pos), cytotoxic T cells (CD8posCD11bne9), and decrease of peripheral T 
suppressor cells (CD8posCD11bpos) was shown, suggesting peripheral T cell 
activation in recurrent miscarriage.
In ectopic pregnancy both peripheral T cell and CD4pos T cell populations increased 
as compared to normal pregnancy [99].
In conclusion, it appears that normal pregnancy is related to an increase of 
peripheral CD56bri 9ht NK cells and low peripheral cytotoxic reactivity. In contrast, 
increased numbers of CD56di mCD16pos n K cells and high peripheral cytotoxic 
reactivity seem detrimental to pregnancy.
Role of HLA-G
Of particular interest is the MHC derived (non-classical) class Ib molecule HLA-G. 
HLA-G is expressed at the placental interface in particular by trophoblast cells and is 
the major h La  antigen with prolonged and significant levels of protein expression. In 
this tissue also (transient) expression of HLA-C and E has been observed 
[62,63,112].
HLA-G is one of three non-classical class Ib MHC genes that encodes for a 37 - 39- 
kDa molecule and is associated with ß2-microglobulin. The HLA-G product shows 
86% homology with the HLA-A, HLA-B and HLA-C consensus protein sequences 
[113]. There are 14 known different alleles encoding for HLA-G, resulting in 4 
nonsynonomous changes [114]. HLA-G protein polymorphism is therefore very 
limited, as compared to the classical class la molecules HLA-A, HLA-B and HLA-C. 
HLA-G shows linkage disequilibrium with HLA-A in several populations [115]. HLA-G 
has a shortened cytoplasmic tail as compared to the classical HLA molecules due to 
a stop codon in exon 6. Interestingly, it is suggested that this shortened cytoplasmic 
tail causes the HLA-G peptide complex to be recycled between endoplasmatic 
reticulum and cis golgi. Only loading of high affinity peptides can diminish recycling 
and increase surface expression of HLA-G [116]. Notably, in vitro studies suggest 
that the recycling of HLA class I molecules represents a mechanism of presenting 
exogenous peptides [117].
HLA-G is most likely co-dominantly expressed [118,119] and differs from the 
classical class I molecules in a way that it shows extensive post-transcriptional 
alternative splicing. At least 7 different spliceforms are formed from the full-length 
transcript in the process of alternative splicing resulting in membrane bound and
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soluble HLA-G molecules (Figure 2). Soluble HLA-G molecules are formed due to a 
stop codon in intron 4 preventing translation of the trans-membrane region [113]. 
Whether the G2, G3 and G4 alternative spliceforms are actually expressed on the 
cell surface and functional is still under debate [120-122].
HLA-G mRNA transcripts were found in various human cells and tissues 
[55,113,123]. Early studies using HLA-G specific mRNA probes revealed the 
presence of HLA-G message in both first trimester villous and extra-villous 
cytotrophoblasts whereas villous syncytiotrophoblasts were negative [124]. Staining 
with antibodies specific for class I molecules confirmed the presence of class I 
proteins in all extra-villous and absence in villous trophoblast populations [125]. 
However recent studies, using an array of HLA-G specific monoclonal antibodies, 
have shown that HLA-G protein expression seems restricted to extra-villous 
trophoblast populations. Antibodies were generated against various HLA-G epitopes 
resulting in recognition ofoverlapping trophoblast populations [126-128].
Trophoblast cells also produce soluble HLA-G that has been detected in maternal 
plasma and amniotic fluid [129-131]. In vitro data on the function of sHLA-G shows 
that sHLA-G, like the classical soluble class I molecules, is able to induce apoptosis 
in CD8pos T cells [132,133]. Furthermore, in allogeneic mixed lymphocyte cultures 
recombinant sHLA-G affected the Th1/Th2 cytokine levels [134].
Initially, it was suggested that the expression of HLA-G was confined to the feto- 
maternal interface. It has now become evident that this is not the case, HLA-G 
protein might be expressed in thymus [135] and malignant tissue [136,137] or can 
either be induced in these tissues under influence of cytokines [138-140]. 
Interestingly, it has been suggested that expression of HLA-G in heart graft biopsies 
is related to graft survival and that HLA-G in psoriasis may act as inhibitory feedback 
to infiltrating T cells [141,142]. However, the expression of HLA-G under these 
pathological conditions shows inconsistent results hampering interpretation. Finally, it 
has been reported that sHLA-G is produced by the CD4pos fraction of peripheral 
blood mononuclear cells in allogeneic mixed lymphocyte cultures [143].
The actual signal that triggers expression of HLA-G in trophoblast cells is unknown. 
Reports on the expression of HLA-G before implantation, in ectopic pregnancy and 
molar pregnancy suggest an autonomous regulation [144,145]. Expression of HLA-G 
putatively declines during the course of pregnancy implicating overall changes in 
relation to immune competent cells, as indicated by the concomitant decrease in the 
number of NK cells [55,146-148]. Whether HLA-G expression in trophoblast cells can 
be induced by IFN -y is still under debate [149]. NK cells are the main source of IFN-y 
and should compromise pregnancy through a Th-1 pathway. There are indications 
that the expression of HLA-E can be induced by IFN-y [149]. Regarding expression 
of HLA-E, it has been shown that HLA-G derived leader peptides are able to stabilize 
the surface expression of HLA-E in vitro [93,150,150,151]. More importantly, the 
combination of HLA-E with the HLA-G leader peptide leads to a HLA-E-peptide 
complex with very high affinity for the activating NKG2C receptor, triggering 
cytotoxicity [152]. Therefore expression of HLA-E seems linked to the autonomous 
expression of h La -G, in function HLA-G dictates an effect that might be amplified or 
even counteracted by HLA-E [122]. Suppression ofthe HLA-A and HLA-B molecules 
in trophoblast cells is a consequence of repressed IFN-y induced promoter 
transactivation [149,153]. Moreover, lack of class II expression is due to class II 
transactivater promoter hyper-methylation [154,155]. The effect of expression of 
HLA-C by trophoblast cells is not resolved. The KIR group of receptors have 
specificity for particular classical class I associated epitopes (i.e. HLA-C) [156].
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Expression of HLA-C by the trophoblast cells at the feto-maternal interface implicates 
that the KIR receptors that recognize HLA-C alleles can be relevant for fetal allo- 
recognition. Data obtained from transplantation shows only a minor role for HLA-C 
mismatches in T cell alloreactivity but could play a role in graft versus host disease 
through KIR expressed by NK cells [157].
In vitro studies have shown that the cytotoxic reactivity and cytokine production of NK 
and T cells against HLA-G expressing target cells of various origin was inhibited 
[158-162], suggesting an in situ function for the HLA-G expressing extra-villous 
trophoblast cells that are in close contact with the decidual maternal immune 
competent cells. In particular the recent finding that soluble HLA-G seems able to 
induce apoptosis in activated T-cells, suggests an immune regulatory role in both 
maternal and fetal immune system [132]. It has been shown that the interaction of 
HLA-G with T cells can be mediated through CD8. The CD8 molecule greatly 
enhances the sensitivity of T cell antigen recognition through co-stimulation. HLA-G 
is bound by CD8 with an affinity similar to that of classical class I molecules [163]. 
Interestingly, HLA-E is bound to CD8 with very low affinity, similar to classical class I 
molecules which are unable to mediate cell-cell adhesion.
Although HLA-G, like class la molecules, appears to be a functional HLA molecule 
with regard to presentation of pathogen-derived peptides to T-cells, the limited 
protein polymorphism indicates that its role in mediating immune responses through 
the T cell receptor is restricted [164]. NK cells are of particular interest when 
considering HLA-G, since NK cells are abundantly expressed at the feto-maternal 
interface and have receptors for HLA-G, HLA-C and HLA-E.
Viewed in retrospect, the feto-placental unit displays several characteristics of 
immune privilege like skewing of immune competent cells that potently produce 
cytokines, distinct expression patterns of class I and class II molecules and 
expression of Fas-Fas-L. In analogy to the ACAID model it can be suggested that 
HLA-G expression by trophoblast cells constitutes a signal that shifts local production 
of cytokines by NK cells in such a way that detrimental local or peripheral activation 
against the fetal alloantigens is prevented. Therefore, deviations in this interaction 
between HLA-G and immune-competent cells at the placental interface could be a 
critical one in determining the outcome of pregnancy and may be involved in the 
etiology of recurrent early miscarriage or preeclampsia.
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Objectives and outline ofthis thesis
The objective of this thesis is twofold. The first aim was to study HLA-G and its 
putative interactions with immune competent cells and NK cells in particular, the 
second aim was to determine the role of these interactions in the etiology and 
pathophysiology of recurrent miscarriage and preeclampsia by which more insight is 
gained in the immunological adaptation needed for successful pregnancy.
In chapter 2, HLA-G protein expression in trophoblastic tissue is studied. 
Subsequently, the distribution of HLA-G mRNA spliceforms in normal pregnancies 
and pregnancies affected by preeclampsia is being looked at (chapter 3). The 
expression of soluble HLA-G in amniotic fluid of pregnancies with offspring affected 
by a neural tube defect (chapter 4a) and that related to the fetal sex was 
subsequently described in chapter 4b. In chapter 5 the effects are studied of 
pregnancy on the cytotoxic capacity and subset composition of peripheral NK cells. 
Finally in chapter 6, a study is presented using an in vitro model on the effects of 
membrane bound HLA-G on the functional capacity of peripheral T and NK cells.
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Abstract
The interaction between decidual NK cells and alloantigens expressed on foetal 
trophoblast cells are thought to be essential for successful implantation and 
placentation. Consequently, a disturbed interaction during the first trimester of 
pregnancy might well lead to a subsequent pregnancy failure. We investigated the 
expression of HLA-G and NK cell markers in tissue sections from recurrent 
miscarriage (n=9), ectopic tubal pregnancies (n=5) and two hysterectomy specimen 
of healthy pregnancy as well as decidual biopsies (n=9), were used as controls. We 
show in normal pregnancy not only a decrease, but also a morphological change in 
CD56pos NK cells upon interaction with HLA-G expressing trophoblasts. The cells 
appear to be transitioning from a blast-like (activation) state into a state of apoptosis. 
The number of CD16pos NK cells was low. In contrast, in recurrent miscarriage tissue 
a sustained NK cell marker expression of both CD56 and CD16 was paralleled by a 
decreased expression of HLA-G. No morphological changes from the blast-like stage 
were apparent. Finally, in ectopic pregnancies HLA-G expression in the absence of 
decidual NK cells was associated with a disturbed trophoblast differentiation. In 
pathological pregnancies we show an in situ altered phenotype of trophoblast and 
NK cells.
Introduction
Evidence is accumulating that some idiopathic pregnancy disorders might have an 
immunological background [1]. The presence of foetal cells in the maternal 
circulation [2] clearly shows that the placenta is not an immunological barrier. 
Furthermore expression of paternally MHC derived HLA molecules at the foetal- 
maternal interface [3-5] can be expected to lead to recognition of the foreign 
antigens by the maternal immune system. This stresses the need for modulation of 
the maternal immune response. This modulation of the local immune system might 
take place in the form of a re-direction or suppression of uterine NK -  and to a lesser 
extent T cell responses upon recognition ofthe paternal antigens.
Of particular interest is the MHC derived (non-classical) class Ib molecule HLA-G. 
HLA-G is expressed at the placental interface in particular by the trophoblast cells 
and it is the major HLA molecule with prolonged and significant levels of protein 
expression. HLA-G is most likely co-dominantly expressed [6] and differs from the 
classical class I molecules in a way that it shows low polymorphism at the protein 
level, a short cytoplasmatic tail, extensive post-transcriptional alternative splicing and 
protein expression which is highly restricted.
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Early studies using HLA-G specific mRNA probes revealed the presence of HLA-G 
message in both first trimester villous and extra-villous cytotrophoblasts whereas 
villous syncitiotrophoblasts were negative [7]. Staining with antibodies specific for 
class I molecules confirmed the presence of class I proteins in all extra-villous and 
absence in villous trophoblast populations [8]. Antibodies were generated against 
various HLA-G epitopes resulting in recognition of overlapping trophoblast 
populations [9-12]. Reactivity against villous core components appears to be the 
major difference of the putative HLA-G specific antibodies. With regard to the 
restricted expression, it has recently been reported that HLA-G protein might be 
expressed in malignant tissue [13] and thymus [14] as well.
In vitro studies have shown that the cytotoxic reactivity of uterine NK and T cells 
against HLA-G expressing target cells of various origin was inhibited [15-17]. This 
suggests that the interaction between HLA-G and immuno-competent cells at the 
placental interface could be a critical one in determining the outcome of pregnancy. 
In this regard it appears promising to look for deviations in these interactions by 
studying early pregnancy disorders of unknown aetiology.
It has been estimated that 1.0% of reproducing couples will suffer from recurrent 
unexplained terminations of early pregnancies [1]. In case of ectopic pregnancy most 
implantation occurs in the tubal duct. [18]. Both disorders occur during 
implantation/placentation when trophoblast proliferation and differentiation is most 
crucial. It is therefore well conceivable that an altered expression of HLA-G might be 
associated with such pregnancy failure.
To assess the validity of this hypothesis we here report the results of a study on 
HLA-G protein expression in combination with the distribution of maternal NK cells in 
tissue obtained from recurrent spontaneous miscarriage and ectopic pregnancy.
Materials and Methods 
Study groups
We studied tissue obtained from two hysterectomy specimens of otherwise healthy 
pregnancies at 12 and 13 weeks of menstrual age respectively, diagnosed for 
cervical carcinoma. These specimens gave additional insight in the HLA-G 
expression and NK cell distribution in the less superficial layers of decidua. 
Additionally, decidual biopsies of 9 control women were obtained inadvertently as 
part of a routine procedure of chorion villous biopsy by means of a flexible bended 
forceps (2mm). Initially the biopsies were kept in Hanks buffered saline solution 
(Merck, Hohenbrunn, Germany). After light microscopically establishment of the 
nature ofthe biopsy they were rejected for karyotyping and put into formaldehyde.
A group of 9 women was studied with a history of recurrent spontaneous 
miscarriages, a population in part previously described, but without overlap in 
material studied [19-21]. A miscarriage was defined as a spontaneous pregnancy 
loss before 16 weeks menstrual age. Only women with a history of at least two 
consecutive spontaneous idiopathic miscarriages before 16 weeks menstrual age 
with the same partner were included. Women were excluded in case of 
chromosomal rearrangement in either partner, Lupus coagulant, anti-cardiolipin 
antibodies, or medication used to treat disorders other than vitamin B6 and B12 
deficiencies, diabetes mellitus, polycystic ovarian syndrome or thyroid dysfunction. 
Women received folic acid supplementation (0.5-mg daily) over a period of at least 2 
months preceding conception. In these 9 women, trophoblastic tissue samples were 
collected after spontaneous miscarriage or curettage of non-vital pregnancies
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diagnosed by ultra-sonography. These 9 women had experienced on average 5 
miscarriages (range 3-9) with the index pregnancy being the most recent pregnancy. 
The mean menstrual age ofthis miscarriage tissue was 8.9 weeks (range 4.3-14.6). 
We finally obtained tissue from 5 ectopic tubal pregnancies by means of tubal 
extirpation at a mean menstrual age of 6.9 weeks (range 5.6-8.3).
The Institutional Review Board of the University Medical Centre Nijmegen approved 
the study and women gave written informed consent, before participation.
Immuno-histochemisty
To reveal HLA-G expression and NK cell distribution in the tissues, we employed an 
immuno-histochemical method using formaldehyde fixed tissue slides and HLA-G 
and NK cell specific monoclonal antibodies. Tissues were dissected and snap frozen 
in liquid nitrogen or fixed for 2 to 4 hours in 4% neutrally buffered formaldehyde and 
embedded in paraffin using an automated tissue processor (Tissue-Tek® VIP150; 
Sakura) under standard conditions for surgical biopsies. Four micrometer sections 
were cut, mounted on SuperFrost/Plus glass slides (Menzel-Gläser, Germany) and 
dried overnight at 37 0C. HLA-G expression and NK cell antigens were demonstrated 
by standard immunohistochemical procedures using antibodies described in Table 1. 
Paraffin sections were dewaxed in xylol and methanol, and endogenous peroxidase 
was blocked for 15 minutes in 1% H2O2 in methanol. This was, depending on the 
primary antibody used, followed by unmasking of antigens by enzyme digestion with 
pronase (0.5%) or microwave treatment (buffered 0.01 M citrate solution, pH 6.0). 
Antibodies were diluted in phosphate buffered saline containing 0.05% Tween-20 
(PBST; Merck, Hohenbrunn, Germany) and 1.0% BSA (PBSTB; Sigma, Steinheim, 
Germany). All incubations were at 37oC and washings between the incubations were 
performed in PBST. Pre-incubating the slides for 10 minutes in PBSTB reduced 
background staining. Excess buffer was wiped off and slides were incubated with the 
primary antibodies for 1 hour, followed by incubation with biotinylated horse anti­
mouse (1/200; Vector Laboratories, Burlingame, USA) and avidin-biotin-horseradish 
peroxidase complex (ABC; Vector Laboratories) for 30 minutes. Finally, peroxidase 
was visualised with 0.05% diaminobenzidine (DAB; Sigma)/ 0.15% H2O2 (Merck) in 
PBS/0.65% Imidazol (Merck; pH 7.7) for 5 minutes at room temperature. Specimens 
were counterstained with hematein and mounted in Permount (Fisher Scientific, Fair 
Lawn, NJ). To determine the specificity of staining, slides were incubated with 
isotype matched negative control antibodies directed against Aspergillus Niger 
glucose oxidase (Dako, Glostrup, Denmark).
We set out to compare the staining pattern of the CAM5.2 antibody, a pan- 
trophoblast marker to the staining pattern of the HLA-G specific monoclonal 
antibodies 4H84, 87G, 16G1 and BFL.1. Because of the extremely small size of the 
(miscarriage) tissue, we had no choice but to use formaldehyde fixed preparations. It 
thus appeared that only the 4H84 antibody gave significant staining of trophoblast 
cells with acceptable levels of background staining. The 4H84 antibody was induced 
against a peptide derived from the a-1 domain and should therefore recognise all
Table 1: Antibodies used to characterise HLA-G expression and NK cell antigens.
Clone specificity isotype Reference pre-treatment dilution
4H84 HLA-G lgG1 [12] microwave 1/100
CAM5.2 cytokeratin lgG2a Becton Dickinson, Erembodegem, B pronase 1/20
1B6 CD56 lgG1 Novocastra, Peterborough, UK microwave 1/50
DJ130c CD16 lgG1 Dako, Glostrup, DK - 1/100
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HLA-G isoforms, [12]. Staining intensity of the different antibodies was scored 
independently by 2 pathologists. The following subjective index was used: ' no 
staining, + some cells positive some negative, ++ strongly positive, +++ very strongly, 
absence of cell populations was scored as not present. Digital images were recorded 
using a Leica Dialux transmission microscope (Leica, Wetzlar, Germany) equipped 
for digital image capture with a 3CCD color video camera (DXC-950P; Sony, Tokyo, 
Japan) and a computer-interfaced frame grabber (Intellicam; Matrox Electronic 
Systems, Dorval, QC, Canada). To quantify differences in HLA-G expression the 
luminosity of the digital images was analysed by means of Adobe® PhotoShop® 5.5 
software. In images of serial sections stained with 4H84 and CAM5.2, rectangular 
selections were superimposed, inverted to negative and the average luminosity 
determined. Luminosity ratios of 4H84/CAM5.2 were calculated to exclude effects of 
background staining.
Results 
HLA-G and NK cell expression in normal pregnancy.
As known during early pregnancy tree like structures called villi evolve from the 
embryonic sac and attach to uterine endometrium. Upon contact the endometrium 
and stroma is decidualised, the maternal spiral arteries are relayed and fill the inter 
villous space with blood thereby forming the haemochorial placenta. At places where 
the foetal villi anchor to the decidua, a cell column of proliferating cytotrophoblast is 
formed (Figure 1A: frames A and B, area marked av). Table 2 shows the 
expressionof HLA-G as stained by the 4H84 antibody in trophoblast tissue from 2 
hysterectomy preparations and 9 decidual biopsies. In the hysterectomy preparations 
we observed that these cell columns display a gradient of increasing staining 
intensity for 4H84 towards the decidua (Figure IA: frames A and B area marked cc). 
Upon contact with the decidua, the cell column cells start differentiating and migrate 
into the decidua thereby forming a population of intermediate extra-villous 
trophoblast cells whilst retaining a 4H84 staining intensity similar to that of the most 
proximal cell column cells. These intermediate trophoblast cells further migrate 
towards the myometrium and differentiate thereby forming intra-mural and
Table 2: Expression oftrophoblast and NK cell markers in tissue collected from two 
hysterectomy specimen (H) of early pregnancies and 9 decidual biopsies (DB) of 
pregnancies of normal neonatal outcome.___________________________________
sample
st vct ecvtp
4H84
ecvti ET st vct ecvtp 
monoclonal antibodies
CAM5.2
ecvti ET decidual
1B6
decidual
DJ130c
H1 - - +++ +++ +++ + + + + + + + + + + + + + + + ++ +
H2 - - +++ +++ +++ + + + + + + + + + + + + + + + ++ +
DB1 - - +++ +++ np + + + + + + + + + + + + np + -
DB2 - - +++ +++ np + + + + + + + + + + + + np + -
DB3 - - +++ +++ +++ + + + + + + + + + + + + + + + + -
DB4 - - +++ +++ np + + + + + + + + + + + + np + -
DB5 - - +++ +++ np + + + + + + + + + + + + np - -
DB6 - - +++ +++ np + + + + + + + + + + + + np + -
DB7 - - +++ +++ np + + + + + + + + + + + + np - -
DB8 - - +++ +++ np + + + + + + + + + + + + np + +
DB9 - - +++ +++ np + + + + + + + + + + + + np - +
st: syncytio trophoblast, vct villous cytotrophoblast, evctp proliferating extra villous trophoblast, evcti 
invading evct, ET: endovascular trophoblast, np: not present, - no staining, + some cells positive some 
negative, ++ strongly positive, +++ very strongly positive.
40
HLA-G and NK cells in recurrent miscarriage and ectopic pregnancies
1A
1B
D: 4H84 250X np inftHrattoTi E->DJ130C 250X no infiltration 
5 * * *
F Sj B6»£50X-no infiltration », - •* s 
1 * V' -
f  9 9  .
■ <11 *
A à .  .» -  , * .  • .
Figure 1: 1A: Shown are representative examples of staining for 4H84, CAM5.2, DJ130C 
and 1B6 in a hysterectomy preparation of an otherwise healthy pregnancy. Frames A, B and 
C show serial sections of an anchoring villus stained for 4H84 (A and B) and CAM5.2 (C) at 
40x (A) and 100x (B, C) magnification. A and B show very strong staining for 4H84 of extra- 
villous trophoblast cells, thereby exceeding staining of CAM5.2 (C). 1B: Frames D through L 
show serial sections stained for 4H84 (D, G, J), DJ130C (E, H, k ) and 1B6 (F, I, L) at 250x 
magnification of respectively trophoblast free decidua (D, E and F), decidua at the marginal 
zone of the placental bed (G, H and I), and decidua at the centre of the placental bed (J, K 
and L). The phenotype of 1B6 positive NK cells changes upon contact with 4H84 positive 
extra-villous trophoblast (compare frames F and I). 1B6 positive NK cells become blast like 
(frame I), whereas prolonged contact leads to loss of 1B6 expression while the NK cells 
reduce in size and with condensed nuclei (frame L). av anchoring villus, cc cell column, d 
decidua
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endo-vascular populations. Finally at the junction with the myometrium, 
differentiation/migration is halted, resulting in the multi nucleate placental bed giant 
cells. All populations of extra-villous trophoblast were stained by 4H84 with an 
intensity similar to the strongest staining cells of the cell column. In contrast to the 
extra-villous trophoblast populations we did not observe 4H84 specific staining of 
both villous syncytio- and cytotrophoblast cell populations or any villous core 
components (Table 2). In the 9 decidual biopsies we observed expression of HLA-G 
and cytokeratin similar to that found in the hysterectomy preparations. We concluded 
that in the hysterectomy preparations and decidual biopsies the HLA-G expression 
pattern and levels correspond with those observed in previous studies on material 
collected from elective terminations of pregnancy [11,12].
Upon decidualisation of the endometrium, the extra villous trophoblast cells come in 
close contact with the maternal NK cells and large mesenchym cells. To study the 
expression of NK cell markers and to be able to distinguish peripheral and uterine 
NK cells, we used antibodies directed against either the CD16 or CD56 antigen 
(Figure 1B). The DJ130c antibody directed against the CD16 antigen strongly stain 
peripheral NK cells. Whereas the 1B6 antibody directed against CD56 weakly stain 
peripheral NK cells, it shows strong staining of decidual NK cells. DJ130c staining 
was restricted to NK cells found in the proximity of the small blood vessels with a 
strong staining intensity and places with focal decidual necrosis. In comparison, 
DJ130c staining intensity of decidual NK cells was hardly detectable. In the 
hysterectomy preparations strong dense staining for 1B6 is mainly found in decidua 
not yet invaded by trophoblast cells (Figure 1B frames D, E, F). Upon contact with 
invading trophoblast at the marginal zone of the placental bed, NK cells enlarged and 
1B6 expression although more diffuse seemed to increase (Figure 1B frames G, H, 
I). Finally, 1B6 staining of placental bed NK cells, in prolonged contact with 
trophoblast, almost completely decreased while NK cells reduced in size and the 
nuclei condensed (Figure 1B frames J, K, L). This shift in staining intensity supports 
the interaction between trophoblast invasion and NK cell distribution and suggests a 
role for HLA-G. Overall the decidual biopsies showed expression of CD16 and CD56 
similarto the hysterectomy preparations (Table 2).
HLA-G and NK cell expression in recurrent miscarriage tissue.
In all preparations where extra-villous trophoblast cells were present, HLA-G was 
expressed in tissue obtained from recurrent miscarriage (Figure 2, Table 3). At 
places where the foetal villi anchored to the decidua, a cell column of proliferating 
cytotrophoblast can be seen in which we observed a gradient of increasing staining 
intensity for 4H84 towards the decidua. Upon contact of the cell column with the 
decidua cells migrate into the decidua and form a population of intermediate extra 
villous trophoblast that differentiate into intra-mural and endovascular trophoblast 
cells, all staining for 4H84. Staining of the placental bed giant cells could not be 
elucidated due to their absence caused by the nature of the miscarriage material. 
Thus the 4H84 staining pattern of the 3 observed extra-villous trophoblast 
populations in miscarriage tissue resembled that of the hysterectomy preparation. 
However, when looking at the staining intensity we observed a marked difference. 
For this purpose we compared in serial sections the ratio of staining intensities of 
4H84 to CAM5.2 between both miscarriage and hysterectomy tissue. While the 
CAM5.2 staining intensity was similar between the preparations (compare figure 1A, 
frame C to figure 2, frame C), remarkably in material obtained after miscarriage the 
ratio between 4H84 and Ca M5.2 staining at the anchoring site of the villi appeared
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decreased as compared to the hysterectomy preparation (compare of figure 1A 
staining ratio of frames B and C to Figure 2 frames staining ratio B and C). We 
observed this phenomenon in all preparations where anchoring villi were present. In 
an effort to quantify this decrease we analysed the luminosity of the (inverted) digital 
images by means of Adobe® PhotoShop® 5.5 software. This resulted in a mean 
luminosity ratio of 4H84/CAM5.2 staining of 0.91 in recurrent miscarriage (n=6) and 
1.11 (n=11) in hysterectomy preparations and decidual biopsies resulting in a 
significant difference of 0.20 (T-test p<0.018). This clearly suggests a decreased 
expression of HLA-G in tissue obtained after recurrent miscarriage.
With the observation of a decreased expression of HLA-G we were interested 
whether this could affect the distribution of the maternal NK cells in the decidua 
(Figure 2, frames D, E, F). In the hysterectomy material, DJ130c staining was only 
observed in secretory endometrium and some isolated areas of focal superficial 
decidual necrosis. Staining with a granulocyte specific marker revealed that these 
areas were infiltrated with granulocytes known for their expression of CD16 (data not 
shown).
Whilst DJ130c staining of lymphocytes in hysterectomy material was restricted, in 
miscarriage tissue lymphocytes localised in decidua basalis were abundantly stained 
(figure 2, frame E). Most surprisingly, in 3 out of 9 tissue samples we also found 
CD16 positive (CD56 negative) cells that had infiltrated the chorionic villi. Whereas in 
the hysterectomy preparation 1B6 staining of decidual lymphocytes was low, in 
contrast, in miscarriage tissue both 1B6 and DJ130c strongly stained the decidual 
NK cells. This altered NK cell phenotype could point to a disturbed interaction 
between trophoblast and NK cells and might be caused by the decreased expression 
of HLA-G.
Table 3: Expression of trophoblast and NK cell markers in tissue collected from 9 
women after recurrent miscarriage at 8.9 weeks (range 4.3-14.6) of gestation._____
st vct ecvtp ecvti ET st vct ecvtp ecvti 
monoclonal antibodies
ET decidual decidual
sample 4H84 CAM5.2 1B6 DJ130c
1 np np np +++ - np np np +++ + +++ +++
2 - - np np np +++ +++ np np np +++ +++
3 - - - ++ + +++ +++ +++ +++ + +++ +++
4 np np np +++ + np np np +++ + +++ +++
5 np np np +++ - np np np +++ + +++ +++
6 np np np np np np np np np np +++ +++
7 np np np np np np np np np np +++ +++
8 - - + + + + + + + + +++ +++
9 - - ++ ++ np +++ +++ +++ +++ np +++ +++
st: syncytio trophoblast, vct villous cytotrophoblast, evctp proliferating extra villous trophoblast, evcti 
invading evct, ET: endovascular trophoblast, np: not present. - no staining, + some cells positive some 
negative, ++ strongly positive, +++ very strongly positive.
HLA-G and NK cell expression In ectopic pregnancies.
We observed that HLA-G was expressed on all extra-villous trophoblast cell 
populations in ectopic pregnancy (Table 4). Concerning expression of HLA-G in 
ectopic trophoblast, due to the absence of a decidual layer it was difficult to compare 
the morphology of the "tubal placental bed" to that of an uterine pregnancy (compare 
Figure 3, frame A to figure 1A, frame A). Although we could recognise structures 
similar to the anchoring villi, we also observed marked differences. Most striking was 
the observation that pre and end stages of trophoblast differentiation seem to be 
present in close proximity of each other. Multi nucleate giant cells, positive for 4H84
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Figure 2: Shown are representative examples of staining for 4H84, CAM5.2, DJ130C and 
1B6 in tissue from recurrent miscarriage. Frames A, B and C show serial sections of an 
anchoring villus stained for 4H84 (A and B) and CAM5.2 (C) at 40x (A) and 100x (B, C) 
magnification. Although extra-villous trophoblast stains for 4H84, the ratio 4H84/CAM5.2 is 
decreased as compared to normal pregnancy (compare staining intensity ratio of frames B 
and C and compare to figure 1A, frame B versus C). Frames D, E and F show serial sections 
of decidua stained for 4H84 (D), DJ130C (E) and 1B6 (F) at 250x magnification. Both 
DJ130C and 1B6 show strong staining of NK cells. 
av anchoring villus, cc cell column, d decidua
Figure 3: Shown are representative examples of staining for 4H84, CAM5.2, DJ130C and 
1B6 in ectopic tubal pregnancies. Frames A, B and C show serial sections of an anchoring 
villus stained for 4H84 (A and B) and CAM5.2 (C) at 40x (A) and 100x (B, C) magnification. 
Clearly present are the giant multi nucleate trophoblast cells with varying levels of 4H84 
staining (A and B arrowhead). Frames D, E and F show serial sections of the tubal 
implantation site stained for 4h 84 (D), DJ130C (E) and 1B6 (F) at 250x magnification. There 
is no significant staining of 1B6, DJ130C predominantly stains polymorphonuclear cells. 
av anchoring villus, cc cell column
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(figure 3, frames A and B see arrowheads), resembling the placental bed giant cells 
in the hysterectomy preparations were found intermingled with the highly proliferative 
cytotrophoblast of the cell column (figure 3, frames A and B area marked cc). In 
analogy with the placental bed giant cells these multi nucleate giants cells could 
represent an end stage in trophoblast differentiation. To find these pre and end stage 
trophoblast cells at the same place suggests a deranged regulation of trophoblast 
differentiation in ectopic pregnancy. Furthermore there were 4H84 positive cells that 
could be identified as endovascular trophoblast cells present in lacunae that 
resembled blood vessels. This could indicate that although trophoblast differentiation 
was changed, these cells are in part still able to effectuate their putative function, 
possibly through the expression of HLA-G.
With the observation that HLA-G was expressed at the interface of trophoblast cells 
and tubal serosa or mucosa in ectopic pregnancy we still wondered whether this 
expression of HLA-G could affect NK cells. Due to the absence of a “real decidua” 
we expected and indeed found no significant staining for 1B6 and or DJ130c at the 
transition where trophoblast cells invaded the tubal serosa (Figure 3, frames D, E 
and F). The only expression was found on peripheral NK cells in blood vessels lining 
the tuba and in the large blood filled lacunae surrounding the villi. This could indicate 
that although HLA-G expression is switched on, the presence of a decidual layer is 
crucial for trophoblast differentiation.
Table 4: Expression of trophoblast and NK cell markers in tissue collected from 5 
ectopic pregnancies at 8 weeks (range 5.6-8.3) of gestation.____________________
st vct ecvtp ecvti ET st vct ecvtp ecvti ET decidual decidual
monoclonal antibodies
sample 4H84 CAM5.2 1B6 DJ130c
1 np np np + np np np np +++ np np np
2 np np np ++ np np np np +++ np np np
3 - - ++ ++ ++ +++ +++ +++ +++ +++ np np
4 np np +++ +++ np np np +++ +++ np np np
5 - - + + np +++ +++ +++ +++ np np np
st: syncytio trophoblast, vct villous cytotrophoblast, evctp proliferating extra villous trophoblast, evcti 
invading evct, ET: endovascular trophoblast, NK natural killer cells, np: not present. - no staining, + 
some cells positive some negative, ++ strongly positive, +++ very strongly positive.
Discussion
In this study we have conclusively shown that HLA-G protein is expressed at the cell 
surface of extra-villous trophoblast cells in tissue from both recurrent miscarriage and 
ectopic pregnancies. With the observation of HLA-G protein expression we ruled out 
the possibility that such abnormal pregnancy outcome could solely be explained by 
the absence of surface HLA-G protein. In control pregnancies the HLA-G expression 
pattern and levels corresponded with those found in previous studies on tissue from 
first trimester elective termination of pregnancies [11,12]. Staining of the 
hysterectomy preparations for the uterine NK cells marker CD56, showed that 
expression intensity at the centre of the placental bed in areas with extensive 
trophoblast invasion was diminished as compared to the marginal zone of the 
placental bed. Furthermore this decrease was paralleled by a morphological change 
in which the CD56pos NK cells seem to be transitioning from a blast-like (activation) 
state into a state of apoptosis upon interaction with HLA-G expressing trophoblasts. 
The presence of focal superficial decidual necrosis in the hysterectomy material was 
described before [22] and might be caused by the remodelling of the spiral arteries
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associated with the redirection of the maternal blood flow. The expression of HLA-G 
in these areas further illustrates that HLA-G not only seems to play a role in 
trophoblast invasion, but also might activate maternal immuno-competent cells 
without compromising pregnancy. This confirms the interaction between Nk cells and 
trophoblast cells that takes place during placentation and suggests a role for HLA-G 
in this interaction.
Although we observed no differences in the distribution of HLA-G over the different 
populations of trophoblast cells, we here present data suggesting that HLA-G 
expression intensity was decreased in trophoblast tissue from first trimester recurrent 
miscarriage. This decrease in HLA-G protein was paralleled by the unusual presence 
of CD16pos lymphocytes. Expression of the CD16 marker is limited in healthy late 
secretory endometrium and during normal early pregnancy [23,24] and therefore the 
presence of CD16 in miscarriage tissue might indicate a disturbed interaction 
between NK cells and the semi-allogeneic trophoblast cells. The limited variation of 
the HLA-G antigen binding site formed by the alpha 1 and 2 domains suggests that 
the HLA-G molecule should always be recognised by the putative receptor on 
maternal effector cells such as NK cells [6]. Inadequate signalling is most likely due 
to the absence or expression of sub-threshold levels of HLA-G or its putative 
receptor. This is in part confirmed by a recent study on the in vitro interaction 
between HLA molecules expressed by tumour cells and NK cells, in which tumour 
cells lacking appropriate HLA class I expression induce infiltration, cytotoxic 
activation and transcription of IFN-gamma in NK cells [25]. Obviously, HLA-G is not 
the sole ligand for uterine NK cells. HLA-E is another class I molecule expressed on 
placental tissues, that interacts with these cells [26]. We have no data on its 
expression level in the tissues studied but it is clear that its expression is influenced 
by HLA-G expression levels. The HLA-G leader peptide is considered a very strong 
binder to HLA-E and stabilises the molecular complex [27]. Thus HLA-G also 
indirectly interacts with uterine NK cells via HLA-E. The found increase in expression 
of the CD16 antigen in miscarriage tissue is in concert with flowcytometrical analysis 
of endometrial biopsies by Lachapelle [28], who found an increase in the cD16 
positive uterine NK cells in late secretory endometrium of women with a history of 
recurrent miscarriage. Another immuno-histochemical study showed that (non­
pregnant) endometrial biopsies from women that subsequently miscarried had 
elevated numbers of CD16pos cells [23]. Regarding the CD16 expression in some 
chorionic villi in miscarriage tissue it could be argued that this reflects non-specific 
binding to the Fcy receptor bearing Hofbauer cells of foetal origin. We never saw any 
non-specific staining of the chorionic villi with our (IgG1) control antibodies. This 
supports our view that these cells are of maternal origin and have infiltrated the foetal 
villi. An important issue to be resolved in future studies is whether changed HLA-G 
expression and NK cell phenotype are related to inadequate trophoblast invasion or 
the result of embrionic/foetal death. However, this will be difficult, as trophoblast 
function and embryonic/foetal viability are intimately linked [29].
The expression of HLA-G in ectopic trophoblastic tissue as described in this study is 
in tune with previous reports [11,30,31] and could indicate that the expression of 
HLA-G is regulated autonomically. The lack of NK cells at the tubal implantation site 
as demonstrated by this study and by Proll et all suggests that recruitment of NK 
cells is not affected by HLA-G [32]. However, the reported deranged differentiation of 
trophoblast in ectopic pregnancy is in concert with the unlimited spontaneous 
trophoblast growth, resulting in tubal rupture. The observation that blood filled 
lacunae and endovascular trophoblast are present in tubal pregnancies might
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indicate (functional) remodelling of tubal blood vessels by trophoblast cells. In this 
regard it is interesting that in a recent study subcutaneous injection of HLA-G 
expressing chorion carcinoma cells into nude mice, led to the formation of similar 
blood filled lacunae instead of neo-vascularization found after injection of non- 
trophoblastic tumour cells [33]. This supports the current view that HLA-G expression 
on trophoblast cells might play a role in the remodelling of spiral arteries and the 
establishment of a haemochorial placenta [34,35]. Finally, it stresses the need for 
strict regulation of trophoblast differentiation, presumably imposed by decidual NK 
cells or stromal cells
In the present study we have shown that in normal pregnancy the expression of the 
common NK cell antigen CD56 was decreased upon interaction with HLA-G 
expressing trophoblast cells. In contrast we have found that a decreased HLA-G 
expression in trophoblastic tissue obtained from women with a history of recurrent 
miscarriages was paralleled by an increased expression of both peripheral and 
uterine NK cell antigens. Finally, we have shown in ectopic pregnancies that 
expression of HLA-G was switched on in the absence of a decidual layer, associated 
with disturbed trophoblast differentiation. These findings are in concert with the 
hypothesis that bi-directional regulation of infiltrating foetal cells and maternal 
immune response is needed for successful pregnancy. The full extent of this 
relationship should be further elucidated.
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Abstract
In spite of emerging data on the in vitro modulatory effects of trophoblast associated 
HLA-G, its in vivo function needs to be resolved. Immunohistochemical studies show 
a decrease in protein expression of trophoblast HLA-G in preeclampsia. Such a 
decrease in protein might be the consequence of a shift in HLA-G mRNA spliceform 
patterns. In an explorative pilot we therefore studied trophoblast HLA-G mRNA 
spliceform distribution in preeclampsia.
Placental samples were collected immediately after caesarian section from 
pregnancies complicated by preeclampsia and / or the syndrome hemolysis, 
elevated liver enzymes and low platelet count (HELLP) and uncomplicated 
normotensive pregnancies as controls. HLA-G mRNA spliceform distribution was 
analyzed using a semi- quantitative RT-PCR procedure.
Analysis of HLA-G spliceform distribution shows a significant increase in G5 isoform 
frequency in preeclampsia. This increase in G5 form encoding for a soluble form of 
HLA-G was, however, notfound in pregnancies complicated by HELLP.
Differential expression of HLA-G spliceforms may play a role in the pathophysiology 
of preeclampsia.
Introduction
Implantation and placentation requires complex interactions between the immuno­
competent cells comprising of Natural Killer (NK) and T cells and the fetal human 
leukocyte antigen (HLA) molecules needed for allo-recognition. This might be 
achieved by the predominant surface expression on the trophoblast cells of HLA-G 
and to a lesser extent HLA-C and HLA-E, in the absence of the classical HLA 
molecules [1].
Although preeclampsia becomes clinically apparent during mid-trimester, there are 
indications such as shallow trophoblast invasion, that its etiology originates during 
early pregnancy when trophoblast cells are most invasive [2]. Also, it has been 
observed that the HLA-G protein expression of this extra-villous trophoblast 
population is decreased in preeclampsia [3-5]. Therefore a link between HLA-G 
expression and trophoblast invasion in preeclampsia has been suggested [6]. This is 
in tune with ex vivo findings showing that preeclamptic trophoblast cell differentiation 
and invasion is greatly reduced, with a concurrent failure to upregulate HLA-G 
expression in these preeclamptic explants [7].
HLA-G is a non-classical class I MHC gene that encodes for a 37 -39 kDA molecule
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which shows limited polymorphism. So far, there are 13 alleles encoding for HLA-G, 
and there is a linkage disequilibrium with HLA-A in several populations [8]. The HLA- 
G product shows 86% homology with the HLA-A, HLA-B and HLA-C consensus 
protein sequences [9]. Due to a stop codon in exon 6 HLA-G has a shortened 
cytoplasmic tail as compared to the classical HLA molecules. At least 7 different 
spliceforms (G1-G7) are formed from the full-length transcript in the process of 
alternative splicing resulting in transcripts encoding for the a l domain in different 
combinations with a2, a3 and transmembrane (TM) region [10]. The G1, G2, G3 and 
G4 transcripts are consequently translated in putative membrane bound proteins 
respectively consisting of (a1;a2;a3;TM), (a1;a3;TM), (a1;TM) (a1;a2;TM) domains 
whereas the G5 (a1,a2,a3), G6 (a1,a3) and G7 (a1) transcripts encode for soluble 
HLA-G molecules. The soluble HLA-G molecules are formed due to the presence of 
a stop codon in intron 4 preventing translation of the transmembrane region and 
cytoplasmic tail [10,11]. HLA-G mRNA transcripts were found in various human cells 
and tissues [11] However, recent studies using an array of HLA-G specific 
monoclonal antibodies have revealed that HLA-G protein expression is still mainly 
restricted to extra-villous trophoblast populations [12]. In vitro functional experiments 
show that not only the full length G1, but also the shorter G2, G3 and G4 are 
expressed at the surface of transfected cells and protect against NK and T cell 
mediated cytotoxicity [13].
The hemolysis elevated liver enzymes and low platelet count syndrome (HELLP) is 
commonly regarded as a further complication of preeclampsia, albeit that the distinct 
clinical manifestation of HELLP and a possible difference in genetic background [14], 
may suggest the involvement of different pathophysiological mechanisms. We 
hypothesize that the afore-mentioned decrease in HLA-G protein expression in 
preeclampsia is the consequence of a shift in HLA-G spliceform distribution. As the 
available antibodies can not unambiguously differentiate between the distinct
Table 1: Population characteristics
P E H E L L P N P
n=12 n=20 n =15
Gestational age (range wks) 35 (28-38) 31* (26-40) 38 (37-41)
Parity 0“ (0 - 1 ) 0* (0 - 1 ) 1 (0-3)
diastolic blood pressure (mmHg) 113 (90-120) 110 (90-120) 75 (60-90)
Hemoglobin (g/dL) 7.5 (6.5-8.5) 7.7 (5.6-8.6) 7.4 (7.0-8.4)
hematocrit (L/L) 0.37 (0.32-.040) 0.36 (0.25-.041) 0.36 (0.34-.041)
platelet count (10a/L) 163° (55-316) 60* (31-93) 222 (151-301)
serum creatinin (^mol/L) 87“ (56-116) 74 (51-144) 59 (54-83)
serum uric acid (mmol/L) 0.39“ (0.24-.055) 0.37* (0.22-0.48) 0.28 (0.18-0.32)
serum aspartate aminotransferase (IU/L) 51“ ° (7-127) 163* (90-1240) 10 (5-32)
serum alanine amniotransferase (IU/L) 46 ° (5-231) 174* (90-965) 7 (4-11)
serum lactic dehydrogenase (IU/L) 404“ ° (232-783) 941* (639-4160) 217 (182-598)
proteinuria (g/L) 3.43“ (0.30-21.5) 3.35* (0.00-6.73) nd
Values are given as median (range). PE: preeclampsia, HELLP: hemolysis elevated liver enzymes and 
low platelets, NP: normotensive pregnancy. Statistically significant difference between, “  :PE  and NP 
only, *:H ELLP and NP only and, ° :P E  and H ELLP  (p<0.02). nd, not determined.
spliceform proteins, a RT-PCR method was used to determine HLA-G mRNA 
spliceform distribution. In an explorative pilot we studied the HLA-G spliceform 
distribution in placental tissue from pregnancies complicated by preeclampsia and/or 
the HELLP syndrome.
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Materials and Methods 
Study group and controls
In this pilot study expression of HLA-G mRNA isoforms in placental biopsies was 
studied in women with preeclampsia (PE, n=12), HELLP syndrome with concurrent 
pregnancy induced hypertension (PIH, n=4) or preeclampsia (n=16) as well as in 
women with normotensive uncomplicated pregnancies (n=15). All preeclamptic, 
HELLP and normotensive control pregnancies were randomly selected and some of 
the subjects participated in a previous non-related study[15]. The Institutional Review 
Board of the University Hospital Nijmegen approved the study and all women gave 
written informed consent, before participation. Preeclampsia and HELLP syndrome 
were defined according to the ISSHP. In short, preeclampsia was defined as a 
diastolic blood pressure exceeding 90 mmHg on two or more consecutive occasions 
more than 4 hours apart or a blood pressure exceeding 110 mmHg on a single 
occasion (phase V Korotkoff sound) and concurrent proteinurea over 0.3 g / L. The 
HELLP syndrome was defined as lactic dehydrogenase > 600 IU/L and both serum 
aspartate aminotransferase and serum alanine aminotransferase > 70 IU/L, in 
combination with thrombocyte counts of less than 100 x 109/L. All HELLP 
pregnancies were complicated by hypertension. All women were delivered by 
caesarian section for fetal or maternal distress without prior contractions. Maternal or 
fetal infection was excluded by means of maternal body temperature and leucocyte 
count and assessment of the fetal heart rate baseline Placental biopsies were taken 
immediately after the birth of the placenta. Placental biopsies obtained from women 
during elective Caesarian sections for cephalopelvic disproportion, breach 
presentation or repeat sections of otherwise un-compromised pregnancies, without 
prior contractions, served as controls. The population characteristics are summarized 
in Table 1.
Trophoblastic tissue samples were dissected and snap frozen in liquid nitrogen within 
20 minutes. An amount of 25 mg tissue was regarded as a minimum for reliable RT- 
PCR.
RT-PCR procedure
Nitrogen stored tissue samples were ground in a nitrogen cooled tube using a 
suitable pestle yielding a homogeneous mixture of which total RNA was isolated 
using the RN-easy kit® (Qiagen, Hilden, Germany), followed by cDNA synthesis 
using the First Strand® cDNA synthesis kit (Pharmacia, Sweden). For cDNA 
synthesis 0.7 to 1.5 —g oftotal RNAwas used.
The synthesized cDNA was used for amplification of specific HLA-G products by 
exon specific primers in a PCR-SSP, carried out with the Amplitaq Gold polymerase 
(Roche, Branchburg, USA), using the hot start technique. The HLA-G exon or intron 
specific 3' primers G.257, G.526, G.-3 and G.-3-4 were used in combination with the 
5' primers G.1225, G.1216 and G.i4b, as described by Moreau et al. [16] (Table 2). 
These six primer mixes recognize different combinations ofthe G1 through G6 splice 
forms that can be identified by the size of the PCR product. All primer combinations 
identifying G1 through G6 were tested positive with trophoblast tissue, albeit of 
distinct origin. The newly identified G7 spliceform should not be recognized by the 
used primer mixes due to a stop codon in intron 2 [10]. Expression of the 
constitutively expressed ß-actin gene was used as positive control and determined 
using the NYBAC3’-NYBAC5’ primer mix [17].
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The PCR conditions were adapted for use on the Geneamp 9600 apparatus (Perkin 
Elmer, Norwalk, USA) and were validated using total RNA extracted from the HLA-G 
expressing JEG3 choriocarinoma cell line [5,11]. In short, forty-five cycles of PCR 
were performed after denaturation at 95°C for 12 minutes, at 95°C for 30 seconds, at 
61°C (primer mixes containing G.257 and G.-526) or 65°C (all other mixes) for 30 
seconds and at 72°C for 1 minute, with an extra extension at 72°C for 5 minutes.
The PCR products were visualized by electrophoresis in a 2% agarose gel, using 
ethidium-bromide staining, followed by digital analysis using the Gel Doc 1000 
system (Biorad, Hercules, USA). Digital images of the PCR products present on the 
gel were recorded and semi-quantitatively analyzed. The digital images of the gel 
were analyzed by overlaying each PCR product (band) by a rectangular box 
enclosing a fixed area. The software calculated the black staining intensity of each 
area. To exclude inter gel variation, for each gel an equivalent area of background 
staining was subtracted from the respective data. Furthermore, all spliceform 
variants for a given sample were run on the same gel and to decrease variation in 
intensities all samples were run in triplicate.
Table 2: Combinations of HLA-G specific primers (with sequence) and expected 
number of basepairs ofthe PCR-products according to Moreau et al. [16].
primer combination 
(sequence)
NYG.1225
(TGA GAC AGA GAC 
GGA GAC AT)
NYG.1216
(GAC GGA GAC ATC 
CCA GCC CC)
NYG.i4b
(AAA GGA GGT GAA 
GGT GAG GG)
NYG.257 980/700/430
(GGA AGA GGA GAC ACG GAA CA)
NYG.526 710/430 - 490
(CCA ATG TGG CTG AAC AAA GG)
NYG.-3-4 - 340 -
(ACC AGA GCG AGG CCA AGC AG)
NYG.-3 - 720/600 410
(ACC AGA GCG AGG CCA ACC CC)
Statistical analysis
Group differences in the population characteristics were analyzed using the test of 
Kruskal-Wallis and appropriate two-sample test of Mann-Whitney U corrected 
according to Bonferroni.
At the first inspection of the data it was recognized that the G4 form of the HLA-G 
expression was not detected in any of the samples and was therefore omitted from 
further analysis. Differences in the expressiom of a specific HLA-G spliceform were 
analyzed both quantitatively, as percentage of the total HLA-G expression of a given 
sample, as well as qualitatively, as presence or absence in a given sample.
A two-way analysis of variance was used to test the differences between the different 
groups of women and within women the HLA-G percentage, i.e. the percentage HLA- 
G expression (G-spliceform) of total expression for statistical significance, separately. 
Prior to the analysis the percentage was angular transformed in order to meet the 
assumptions of normality and homoscedasticity. The dependent variable was the 
(angular-transformed) percentage for a given HLA-G spliceform. The independent 
random variable was “woman”, indicating random variation between the women, and 
the independent class variable was pregnancy group (normotensive pregnancy, 
preeclampsia, HELLP). The appropriate contrast-test was used adjusted according 
to Tukey-Kramer. After back transformation, the medians with 95% confidence
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intervals (Cl) are presented. Logistic regression was used to test for differences 
between women in the three groups in presence of each G-spliceform separately. P- 
values smaller than 0.05 were considered statistically significant.
Results
Population characteristics as depicted in Table 1, show significant differences for 
gestational age and parity.
ln all groups, irrespective of the course of pregnancy, the G1 transcript was the most 
predominant form, found in 70-85% of the samples. The G5 form, however, was 
found in over 80% of the preeclampsia cases as opposed to approximately 40 and 
45% in normotensive and HELLP pregnancies respectively. The G6 spliceform was 
only detected in five cases, distributed over all pregnancy groups, the G4 spliceform 
could not be detected in any ofthe samples.
Figure 1: The quantities of expression by HLA-G spliceform and by pregnancy group (N P : 
normotensive pregnancy, P E : preeclam psia, H E L L P : hemolysis elevated liver enzym es and 
low platelet count syndrom e). For each sam ple the contribution of a specific spliceform w as 
calculated as the percentage of the sum of absolute expression levels of all spliceforms of 
that sam ple (estimated median (•) with confidence intervals (-)).
ln order to relate the HLA-G spliceforms to preeclampsia/HELLP pregnancies, both 
spliceform frequencies and spliceform expression levels were analyzed.
Since we performed a semi-quantitative RT-PCR, absolute expression levels 
between individual samples could not be compared directly. To overcome this 
limitation, the contribution of each spliceform was calculated as a percentage of the 
total HLA-G expression of a given sample, enabling (semi) quantitative analysis 
between samples. To detect group differences the relative spliceform quantities were 
analyzed per spliceform over the preeclampsia, HELLP and normotensive control
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group, after angular transformation. Figure 1 shows the estimated median quanties 
with 95% confidence intervals (Cl) after back transformation. It is evident that G1 (on 
average 50%), irrespective of pregnancy group, is the spliceform with the highest 
level of expression whereas g 2 (on average 4%) and G6 (less than 1%) show low 
levels of expression. However, there were no significant differences between the 
preeclampsia, HELLP and normotensive pregnancy groups in spliceform expression 
levels. Analysis of variance of all hypertensive pregnancies together (preeclampsia + 
HELLP) did not result in a significant difference for any ofthe spliceforms tested. 
Analysis of the spliceform frequencies (Figure 2) showed that irrespective of the 
pregnancy group, G1 was most frequently expressed (on average 80.5%) in contrast 
to the g 6 spliceform that can only be found in 1 out of 10 samples (10.5%). In 
preeclamptic pregnancies the frequency ofthe G5 spliceform (83.3%, Cl: 52.3-95.8) 
is significantly higher as compared to both normotensive and HELLP pregnancies 
with frequencies of respectively 45.0% (Cl: 25.3-66.4) and 40.0% (Cl: 19.9-16.2). 
Therefore, the chance to find the G5 spliceform in preeclamptic pregnancies was 
increased as compared to normotensive or HELLP pregnancies. This can be 
quantified by calculating the odds ratios, resulting in an odds ratio of 7.5 (95% Cl: 
1.20-47.05) and 6.1 (Cl: 1.06-35.35) for the absence of the G5 form in the 
normotensive and HELLP pregnancies respectively as compared to preeclamptic 
pregnancies. However, analysis of variance of the other spliceforms (G1, G2, G3, 
G6) revealed no significant group differences. Analysis of variance of all 
hypertensive pregnancies together (preeclampsia + HELLP) did not result in a 
significant difference for any of the spliceforms tested.
Figure 2: The frequency of HLA-G spliceform expression by pregnancy group (N P : 
normotensive pregnancy, P E : preeclam psia, H E L L P : hemolysis elevated liver enzym es and 
low platelet count syndrome, estimated median (•) with confidence intervals (-)).
ln summary, the G2 spliceform combines a low expression level with an average 
frequency of expression. The G6 spliceform is low in both expression level and 
frequency. The G1 spliceform combines a high expression level with a high 
frequency of expression. The G5 spliceform frequency is significantly increased for 
preeclampsia as compared to normotensive and HELLP pregnancies and 
concurrently the G5 spliceform expression level shows a similar but non-significant 
tendency.
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Discussion
ln this study, we show that both its frequency and relative quantity of trophoblast 
HLA-G G5 mRNA spliceform were increased in preeclampsia as compared to both 
normotensive control and HELLP pregnancies.
An in vitro model by Paul et al. [10] showed that the G5 spliceform is readily 
translated into its protein form. This in contrast to the other two HLA-G mRNA 
transcripts that encode for a soluble form, G6 and G7, which have no detectable 
protein expression. Thus, it is primarily the G5 form that results in soluble HLA-G 
production with all its putative effects on immunoregulation and tissue maturation. ln 
this regard, the G6 and G7 transcript clearly seem less relevant in relation to 
preeclampsia. The G4 spliceform could not be demonstrated in any of the placental 
biopsies.
As preeclampsia is a consequence of failing trophoblast invasion related to smaller 
spiral artery diameter and a more tortuous course resulting in poor maternal- 
placental blood flow [18], it is of interest to consider the role of HLA-G on 
angiogeneses. ln this respect it already has been shown that subcutaneous injection 
of HLA-G expressing human choriocarcinoma cells into (immuno deficient) nude 
mice leads to the formation of blood filled lacunae, analogous to the haemochorial 
placentation. This is in contrast to the neo-vascularization found after injection of 
non-trophoblastic tumor cells [19]. lnterestingly, when looking at the placental bed 
lymphocytes in preeclampsia, an increase in the cytotoxic subset of decidual T cells 
can be observed, suggesting interplay with trophoblast cells and a role for these cells 
in the transformation ofspiral arteries [20].
Regarding the putative presence of soluble HLA-G protein in the maternal circulation 
during uncomplicated and preeclamptic pregnancies [21,22], a systemic effect of the 
soluble HLA-G protein on T cells in preeclamptic pregnancies might be expected [6]. 
lndeed, a study by
Terrone et al. [23] shows that white blood cell counts in preeclampsia were 
decreased as compared to HELLP pregnancies which indirectly suggests a decrease 
of T cells, being the predominant leukocyte sub-population. This is in tune with our 
observation that the *5 transcript was increased in preeclamptic pregnancies but not 
in HELLP pregnancies. lt can be speculated that in both preeclamptic and HELLP 
pregnancies T cells become activated against fetal antigens as a consequence of 
aberrant immuno modulatory function of the trophoblast cells. Hence, HELLP 
pregnancies may lack a decrease in activated T cells (there is no increase of G5 in 
HELLP) and are therefore prone to the systemic effects of this activated T cell 
population. However, caution should be taken when extrapolating changes in mRNA 
data to protein expression. An increase in G5 mRNA might not be correlated to a 
subsequent increase in G5 protein, as transcripts might accumulate due to defects in 
downstream protein translation or subsequent transport to the cell surface [24].
Few studies have investigated the expression of h La -G in preeclampsia and HELLP 
pregnancies [3-5,7]. Colbern et al. show that a reduction in HLA-G RNA (without 
subdivision in spliceforms) in preeclampsia was paralleled by a decrease in 
cytokeratin RNA, indicative for a reduced volume of trophoblast cells [5]. lmmuno- 
histochemical findings by Hara et al. [4], on the expression of HLA-G protein in 
preeclampsia show clusters of extra-villous trophoblast cells with reduced expression 
of HLA-G protein. ln situ hybridization with a probe specific for an untranslated region 
of HLA-G in preeclampsia or HELLP shows reduced or absent expression 
suggesting reduced or absent expression of HLA-G [3]. ln vitro data from Lim et al.
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[7] show that cultures of cytotrophoblast cells isolated from preeclamptic pregnancies 
failed to up-regulate expression of HLA-G protein and mRNA. However, no 
subdivision in preeclampsia and HELLP syndrome or different HLA-G spliceforms 
was made.
The increase of the G5 spliceform in preeclamptic pregnancies as compared to 
HELLP pregnancies suggests a difference in the pathophysiology of preeclampsia 
and HELLP as has been suggested before [14,23,25-27].
ln conclusion, the pathophysiology of preeclampsia seems inherently linked to the 
aberant trophoblast invasion. We show that one aspect of extra-villous trophoblast 
differentiation being the expression of HLA-G in preeclamptic pregnancies may be 
different from that in normotensive or HELLP pregnancies.
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Abstract
Pregnancies affected by a neural tube defect show changes in thymus morphology, 
neonatal and maternal T-cell repertoire. In amniotic fluid levels of soluble HLA-G (an 
immuno-modulatory protein) were found to be significantly lower as compared to 
controls. This may reflect a diminished cell-mediated immunity in neural tube defects.
Introduction
The haemochorial placenta, membranes and amniotic fluid form an interface 
between the developing fetus and the maternal body. They are essential for the 
supply and exchange of nutrients. However, these structures also protect the fetus 
from pathogens and the potentially semi-allogeneic maternal immune system. 
Recent studies showed that trophoblast cells not only shield but also might play a 
role in modulating the maternal immuno competent cells by expressing a distinct 
profile of human leukocyte antigens (HLA). Trophoblast cells are known to 
predominantly express the HLA-G, C and E molecules, whereas class I HLA-A, B 
and class II HLA-DQ, DR molecules seem absent. Expression ofthe low polymorphic 
HLA-G protein is affected by the post-transcriptional process of alternative splicing. 
Until now seven mRNA spliceforms have been identified, three of which encode for 
the soluble forms and four encode for membrane bound forms of the HLA-G protein. 
Studies on in vitro cultures of HLA-G expressing cell lines have shown that 
membrane bound HLA-G is able to inhibit cytotoxicity and cytokine production by T 
and NK cells [1]. This suggests an in situ function for the HLA-G expressing extra­
villous trophoblast cells that are in close contact with the decidual maternal immune 
competent cells. Soluble HLA-G most likely excreted by decidual and amnion 
trophoblast cells, has been identified in maternal plasma and amniotic fluid and may 
act as a specific immuno suppressor during pregnancy [1]. In particular the recent 
finding that soluble HLA-G seems able to induce apoptosis in activated T-cells [2], 
gives rise to the thought that this protein plays a role in the development of the fetal 
immune system.
Thymus development starts from the third pharyngeal pouch thus providing a direct 
route for contact with amniotic fluid and soluble HLA-G until 6 weeks of gestation. 
Neural tube defects are associated with abnormalities of the thymus. The
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observation that both newborn offspring affected by neural tube defects and their 
mothers during pregnancy showed changes in T cell repertoire [3,4] suggests a 
mutual mechanism possibly involving soluble HLA-G. Thus, we investigated the 
soluble HLA-G concentrations in amniotic fluids from neural tube defect affected 
pregnancies and controls.
Materials and Methods 
Study group and control samples
Amniotic fluid was collected by amniocentesis after ultrasound conformation of a 
neural tube defect (n=32), of which 30 spina bifida and 2 anencephalus. As a control 
group amniotic fluid from amniocentesis (15-16 weeks amenorhea) indicated for 
advanced maternal age, was taken with subsequent unaffected neonatal outcome 
(n=37). To evaluate gestational age effects, additional amniotic fluid from otherwise 
uncomplicated term pregnancies delivered by elective Caesarian section was 
obtained (n=6, 39 weeks amenorhea). Amniotic fluid was collected in low protein 
binding tubes (MiniSorp™, Nunc, Wiesbaden, Germany) and stored at -800C until 
analysis.
Sandwich ELISA
The amniotic fluid soluble HLA-G level was measured by a sandwich ELISA, using 
G233 as capturing antibody and 56B as detection. The G233 antibody is directed 
against HLA-G associated with ß2-microglobulin, without known cross reactivity to 
other class I molecules. The 56B antibody is generated against the HLA-G a2- 
domain and stains all populations of HLA-G expressing extra-villous trophoblast. This 
antibody combination should recognize both soluble and membrane shed HLA-G1 
forms. The following ELISA protocol was used. Plates (OrganonTechnika, Oss, 
Netherlands) were coated overnight with 2g/ml G233 capturing antibody in 0.2M 
Carbonate/Bicarbonate buffer pH 9.4 (Pierce, Rockford, USA) at 40C. Plates were 
subsequently blocked by adding 5% (w/v) skimmed milk (Difco, Chicago, USA) in 
washing buffer (PBS containing 0.05% (v/v) Tween-20 (Merck, Darmstadt, 
Germany)) for 2 hours at room temperature followed by washing. Amniotic fluid 
samples were centrifuged at 2000 rpm for 7 minutes and incubated for 4 hours at 
room temperature followed by washing. Biotinylated detection antibody 56B was 
incubated overnight at 40C followed by detection with the streptavidin-peroxidase 
Vectastain Elite ABC kit (Vector labs. Burlingame, USA) and Immunopure TMB 
substrate kit (Pierce, Rockford, USA). All results are depicted as absorbencies 
normalized to a standard pooled amniotic fluid.
Statistical analysis
Group differences were tested using the Wilcoxon-Mann-Whitney U-test, a p-value < 
0.05 was considered statistically significant.
Results
In this study we have assessed soluble HLA-G levels in amniotic fluid to further elude 
its putative role in fetal maturation. For this purpose we studied amniotic fluid 
samples from pregnancies affected by neural tube defects and controls (Figure 1). 
The median normalized absorbency of soluble HLA-G in amniotic fluid of the neural 
tube defect group (median 1.01, range 0 - 7.66) was significantly lower as compared
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to control samples obtained from mid trimester (median 3.8, range 0.57 - 14.7, 
p=0.001) or term pregnancy (median 7.2, range 3.5 - 10.0, p=0.009). The difference 
in amniotic fluid soluble HLA-G levels between mid trimester and term controls was 
not significant (p =0.4303).
Figure 1: Levels of soluble HLA-G in amniotic fluid from pregnancies affected by 
neural tube defect and healthy mid trimester / term control pregnancies. Depicted are 
individual readings (•) and median (-).
Discussion
The soluble HLA-G level in mid trimester amniotic fluid of neural tube affected 
pregnancies was significantly lower as compared to control samples obtained from 
mid trimester and term pregnancy. As the expression of membrane bound HLA-G is 
thought to be maximal during early pregnancy, it is not very likely that this finding is 
confounded by gestational age. Furthermore the difference in amniotic fluid soluble 
HLA-G levels between mid trimester and term samples was, despite the small 
sample size of the latter group, not significant. This finding is in concert with studies 
that found sustained levels of soluble HLA-G in plasma and amniotic fluid throughout 
pregnancy [5].
Whether the decrease in soluble HLA-G in amniotic fluid from pregnancies affected 
by neural tube defects is directly related to the etiology of neural tube defects 
remains speculative. Folate plays an important role in the pathogenesis and 
prevention of neural tube defects. Both in vivo and in vitro test show that folate 
deficiency might be associated with an impaired T cell response [6]. In pregnancies 
complicated by a neural tube defect folic acid might exert a direct effect on the highly 
proliferative trophoblast cell population via impaired DNA synthesis known for folic 
acid deficiency and subsequent decrease in soluble HLA-G concentrations. Another 
explanation for our finding could be an association between HLA-genes and genes 
involved in the development of neural tube defects, which has to be resolved in 
genetic studies [7]. It is from our study not clear whether the low HLA-G
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concentration is due to a decreased expression by the placental tissues and whether 
folate is involved. These are interesting issues forfuture investigations.
As soluble HLA-G is thought to originate from trophoblast cells it is still not clear how 
the molecule is excreted in amniotic fluid. Soluble HLA-G can be detected in 
maternal plasma during pregnancy, presumably produced by extra-villous- 
trophoblast cell populations and may be transported to the fetal circulation and 
subsequently excreted in amniotic fluid. This pathway is in accordance with data 
showing the presence of soluble HLA-G in cord blood. Another possible route is the 
production ofsoluble HLA-G by trophoblast cells situated in the fetal membranes.
In vitro studies have shown that (soluble) HLA-G can act as an immunoregulatory 
molecule. Apoptosis is induced in activated CD8pos cytotoxic T lymphocytes and high 
doses of solubilised native HLA-G have been shown to inhibit cytotoxicity and induce 
a shift from Th1 to Th2 profile in peripheral blood mononuclear cells [8,9]. Our finding 
of low HLA-G together with the increase in cytotoxic T lymphocytes as described by 
Seniz [4] fits this notion. One of the putative functions of soluble HLA-G is to act as 
an immune-suppressive molecule, modulating the maternal immune response to the 
“fetal allograft”. In vitro studies confirm such a role and especially the recent findings 
of Fournel et al. [2] appear promising as they show the ability of soluble HLA-G to 
induce apoptosis in the cytotoxic subset of T lymphocytes. Importantly, this is in 
concert with findings of Seniz [4] that show an increase of maternal cytotoxic T cells 
in pregnancies complicated by neural tube defects. A decrease in soluble HLA-G at 
the feto-maternal interface might therefore shift the maternal immune response away 
from tolerance and tip the balance towards expulsion of the conceptus. This seems 
to be confirmed by an increased incidence of neural tube defects in miscarriage 
tissue. As the presence of common allergens in amniotic fluid has been 
demonstrated, it seems obvious that allergen specific immune responses should be 
suppressed. Soluble HLA-G levels in the fetal circulation might contribute in this 
process and affect T cell levels. Blood samples of newborns affected by neural tube 
defect indeed show a change in T cell distribution as compared to healthy offspring 
[3]. However, the influence of thymal dysplasia on T cell distribution in cases of 
neural tube defects can not be excluded.
In conclusion, we show that the level of soluble HLA-G in amniotic fluid is markedly 
lower in pregnancies affected by neural tube defects, which may reflect an altered 
cell-mediated immunity in these pregnancies which might be associated to folate 
deficiency or thymus dysplasia.
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Summary
Despite putative modulatory effects of HLA-G, its function and expression need 
elucidation. We analysed soluble-HLA-G levels in mid-trimester amniotic fluid (n=64) 
from uncomplicated pregnancies. We show a decrease in soluble-HLA-G levels for 
female offspring as compared to male (p<0.007). This may be a consequence of the 
immuno-modulatory capacity of HLA-G.
Introduction
During early pregnancy trophoblast cells come into contact with maternal decidua, 
thereby shaping an interface needed for foetal development. Where exchange of 
nutrients is essential, the foetus should also be shielded from pathogens and a 
potentially semi-allogeneic maternal immune system. Recent studies showed that 
trophoblast cells not only shield but also might play a role in modulating the maternal 
immune competent cells by expressing a distinct profile of Human Leukocyte 
antigens (HLA). Trophoblast cells predominantly express the HLA-G, C and E 
molecules [1], whereas the classical class I and class II molecules seem absent. 
Although the number of HLA-G allotypes is very restricted, HLA-G shows through the 
post transcriptional process of alternative splicing a unique alternative to create 
diversity, resulting in soluble forms and membrane bound forms ofthe HLA-G protein 
[2,3]. The soluble HLA-G isoforms are a consequence of a stop codon in intron four 
thus preventing translation of the transmembrane domain and cytoplasmic tail. In 
vitro studies have shown that soluble HLA-G (sHLA-G) is able to alter cytokine 
expression by lymphocytes and is able to induce apoptosis in cytotoxic T cells [4,5]. 
Soluble HLA-G protein has been identified in amniotic fluid and maternal plasma 
during pregnancy and in serum from hart graft recipients and melanoma patients [6­
9].
Materials and Methods
In the present study, amniotic fluid samples (n=64) collected by amniocentesis 
indicated for advanced maternal age at 15-16 weeks amenorhea, were assessed for 
the presence of sHLA-G. Pregnancies resulted in deliveries (mean amenorhea 39 
weeks, range 32-42) of children without congenital disorders.
The amniotic fluid sHLA-G levels were assessed by a sandwich enzyme linked 
immuno sorbend assay (ELISA), utilising HLA-G specific antibodies, being G233
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coated to the bottom of the 96 wells plate as capturing antibody and the biotinylated 
56B as detection antibody in combination with streptavidin conjugated peroxidase 
and TMB substrate [10], in press). The G233 antibody is directed against HLA-G 
associated with ß2-microglobulin, without known cross reactivity to other class I 
molecules [11]. The 56B antibody was generated by immunization of Balb/c mice 
with a peptide corresponding to amino acids 138-158 of the a2-domain of HLA-G. 
The 56B antibody was found to recognize denatured HLA-G heavy chain from HLA- 
G transfected K562, 721.221 cell lines and JEG3 cells, and stained all populations of 
trophoblast cells in acetone fixed frozen-sections and formalin fixed parafin sections 
of first trimester pregnancy. Since HLA-G is known to be expressed in particular by 
extra-villous trophoblast populations, 56B probably recognizes more than HLA-G 
alone on these placental sections. The sandwich ELISA showed high responses to 
recombinant HLA-G and native HLA-G in primary trophoblast culture supernatants. 
Measurements were done in triplicate and inter-plate differences were corrected by 
means of a control sample. Group differences were tested using the Mann-Whitney 
U-test.
Results
Measurement of the sHLA-G content of amniotic fluid showed a significant higher 
normalised absorption in male offspring (median 3.76, range 0.67-8.19, n=35) as 
compared to female offspring (median 3.01, range 0.35-6.00, n=29, U-test p<0.007).
Discussion
It might be that soluble HLA-G can act as an immuno-modulating molecule during 
pregnancy. In this case not only to modulate or counteract maternal immune 
competent cells upon recognition of foetal allogeneic major antigens, but also upon 
recognition of so-called minor histocompatibility antigens [12]. Obviously, additional 
minor antigen differences are expected for male offspring (e.g. HY antigen); thus 
evoking a more vigorous maternal immune response that might need to be counter 
balanced by the production of more sHLA-G.
How sHLA-G is conveyed to the amniotic fluid remains speculative. As the presence 
of amniotic fluid in the foetal stomach and lungs indicates ingestion and inhalation by 
the foetus, thereby designating a route for oral or nasal tolerisation. Soluble HLA-G 
with its apoptotic capacity [5] might delete auto reactive T cells and work as an ante­
partum signal for foetal tolerisation. The effects of amniotic fluid soluble HLA-G 
levels on this self/non-self recognition might also be of influence in adulthood and 
result for example in a female predisposition for auto immune disease [13,14].
References
[1] King A, Allan DS, Bowen M, Powis SJ, Joseph S, Verma S, Hiby SE, McMichael AJ, 
Loke YW, Braud VM. HLA-E is expressed on trophoblast and interacts with 
CD94/NKG2 receptors on decidual NKcells. Eur.J.Immunol. 2000;30(6):1623-31.
[2] lshitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with 
primary structures resembling both class I and class II antigens. 
Proc.Natl.Acad.Sci.U.S.A. 1992; 89(9):3947-51.
[3] Hiby SE, King A, Sharkey A, Loke Yw . Molecular studies of trophoblast HLA-G: 
polymorphism, isoforms, imprinting and expression in preimplantation embryo. 
TissueAntigens 1999;53(1):1-13.
72
Amniotic sHLA-G decreased in female offspring
[4] Kanai T, Fujii T, Kozuma S, Yamashita T , Miki A, Kikuchi A, Taketani Y. Soluble 
HLA-G influences the release of cytokines from allogeneic peripheral blood 
mononuclearcells in culture. Mol Hum Reprod JID - 9513710 2001;7(2):195-200.
[5] Fournel S, Aguerre-Girr M, Huc X, Lenfant F, Alam A, Toubert A, Bensussan A, Le 
Bouteiller P. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated 
apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 
2000;164(12):6100-4.
[6] Rebmann V, Pfeiffer K, Passler M, Ferrone S, Maier S, Weiss E, Grosse-Wilde H. 
Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens 
1999;53(1):14-22.
[7] Hunt JS, Jadhav L, Chu W, Geraghty DE, Ober C. Soluble HLA-G circulates in 
maternal blood during pregnancy. Am J Obstet Gynecol 2000;183(3):682-8.
[8] Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, Carosella ED. Implication 
of HLA-G molecule in heart-graft acceptance. Lancet 2000;355(9221):2138
[9] Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble 
human leukocyte antigen--G serum level is elevated in melanoma patients and is 
furtherincreased byinterferon-alpha immunotherapy. Cancer 2001;92(2):369-76.
[10] Van Lierop, M.J.C., Wijnands, F., Loke, Y.W., Emmer, P.M., Lukassen, M., Braat
D.D.M., Meer van de A., Mosselman, S. & Joosten, I. Detection of HLA-G a specific 
sandwich ELISA using monoclonal antibodies G233 and 56B. Mol Hum Reprod, 
2002;4: 776-784.
[11] Loke YW, King A, Burrows T, Gardner L, Bowen M, Hiby S, Howlett S, Holmes N, 
Jacobs D. Evaluation of trophoblast HLA-G antigen with a specific monoclonal 
antibody. TissueAntigens 1997;50(2):135-46.
[12] Simpson E, Roopenian D. Minor histocompatibility antigens. Curr Opin Immunol 
1997;9(5):655-61.
[13] Chiovato L, Lapi P, Fiore E, Tonacchera M, Pinchera A. Thyroid autoimmunity and 
femalegender. JEndocrinolInvest 1993;16(5):384-91.
[14] Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001;2(9):777- 
80.
73
Chapter4B
74
Peripheral Natural Killer cytotoxicity and CD56posCD16pos cells increase during 
early pregnancy in women with a history of recurrent spontaneous abortion
Human Reproduction Vol.15, No.5, pp. 1063-1169, 2000
Chapter 5
75
Chapter 5
76
Peripheral NK cells and pregnancy
Peripheral Natural Killer cytotoxicity and CD56posCD16pos cells increase 
during early pregnancy in women with a history of recurrent spontaneous 
abortion
Peter M. Emmer1, Willianne L.D.M. Nelen2, Eric A.P. Steegers2, Jan C.M. Hendriks3, 
Margret Veerhoek1 and IrmaJoosten1
department of Bloodtransfusion and Transplantation Immunology, 
department of Gynaecology and Obstetrics and
departement of Medical Statistics, University Medical Center Nijmegen, The 
Netherlands
Abstract
For diagnostic purposes we assessed peripheral NK cell cytotoxicity and NK- and T 
cell numbers to assess their putative predictive value in recurrent spontaneous 
abortion. Fourty-three RSA women with subsequent pregnancy, 37 healthy controls 
and 39 women succesfully partaking in an IVF procedure, were included in the study. 
We show that before pregnancy, levels of natural killer cytotoxicity and numbers of 
both single CD56pos and double CD56posCD16pos cells were similar between RSA 
women and controls. But notably, within the RSA group, natural killer cell numbers of 
<12% were strongly associated with a subsequent pregnancy carried to term. 
Supplementation of folic acid led to an increased level of single CD56pos cells, but 
cytotoxic function appeared unaffected. The expression pattern of killer inhibitory 
receptors on CD56pos cells was not different between patients and controls.
A longitudinal study revealed that, compared to controls, in RSA women higher 
numbers of double CD56posCD16pos cells were present during early pregnancy, 
paralleled by an increase in cytotoxic natural killer cell reactivity. The single CD56pos 
population decreased in number. In conclusion, the analysis of peripheral natural 
killer cell characteristics appears a suitable diagnostic tool in RSA. 
Immunomodulation aimed at Nk  cell function appears a promising therapeutic 
measure.
Introduction
About 0.5-1% of couples who are trying to conceive will be suffering from 
subsequent spontaneous miscarriages [1]. Some 80 percent of those losses can not 
be accounted for by chromosomal defects, hormonal disorders or uterine 
abnormalities. Evidence is accumulating that these unexplained miscarriages might 
have an immunological background. The presence of foetal cells in the maternal 
circulation [2] shows that the foetal-maternal interface is not an absolute barrier. 
Since the foetus is semi-allogeneic to the mother and it has conclusively been shown 
that both foetal cells and placental tissues do express the paternally derived and thus 
foreign HLA antigens [3-5], it can safely be assumed that every successful 
pregnancy must be accompanied by redirection or suppression of Natural Killer (NK) 
and T cell reactivity. Fine tuning appears to be an essential feature of the foetal- 
maternal interaction. The consequences of unbalance appear to be particularly 
exemplified by the contrasting findings in endometriosis as compared to RSA 
patients [6]. Apparently, excessive immunosuppression (the Th2 environment 
observed in endometriosis) leads to uninhibited endometrial growth, with
77
Chapter 5
unfavourable outcome. In turn, a greater activation or reduced immunosuppression 
(favouring a Th1 environment, including cytotoxity) leads to insufficient growth and 
maturation. Indeed, elevated expression of T cell activation markers has been 
associated with early pregnancy loss [7]. HLA antigens might well play a pivotal role 
in this process by not only supporting fitness (by exerting influence on survival and 
reproductive success), but also development [8].
The notion that the immune system requires modulation in order to ensure 
successful pregnancy has in the case of r Sa , already led to preventive measures 
like intravenous injection of IgG [9,10] and paternal leukocyte immunisation [11,12]. 
Of particular interest is the role of Nk  cells. During early pregnancy the so-called 
uterine NK cells form the major population of immune competent cells in the 
maternal-fetal interface. These cells carry inhibitory receptors for HLA antigens, most 
notably CD94/NKG2a, CD158a and CD158b [13,14]. At the placental interface HLA- 
G is the major HLA antigen with prolonged and significant levels of protein 
expression, but also (transient) expression of HLA-C has been observed [3,4]. In 
vitro studies with both uterine and peripheral NK cells have shown that the cytotoxic 
reactivity against HLA-G expressing targets of distinct origin was inhibited [15,16]. 
This suggests that the interaction of HLA antigens and NK cells at the placental 
interface could be critical in determining the outcome of pregnancy. So far, few 
groups have studied peripheral NK cell characteristics in r Sa  women. Beer, Kwak 
and co-workers have shown that before and during pregnancy NK cell numbers in 
RSA women are elevated, whereby high numbers appeared predictive of subsequent 
miscarriage [17,18]. Also, evidence has been obtained that NK cell cytotoxic activity 
is increased in RSA women [9,19,20], particularly in those with subsequent 
pregnancy failure. Intravenous IgG treatment and paternal leukocyte immunisation 
have already successfully been used to down regulate NK cell activity [9,20,21].
We here report the results of a longitudinal study comprising pre-and post- 
conceptional data on both NK cell cytotoxicity and NK cell phenotypes in RSA 
women with either a successful or failed pregnancy. Thus, we were able to answer 
whether pre-conceptional NK cell parameters differ between RSA women and 
controls and whether these are indicative of subsequent miscarriage. We assessed 
the changes in NK parameters within groups from pre- to post-conceptional stages 
and how these values differed between RSA women and controls at several points 
during the course of pregnancy. In the course of this study we also assessed the 
effect offolic acid intake on NK cell characteristics.
Materials and methods 
Study group and controls
Over a 2-year period, 142 women with a history of RSA and in part previously 
described [22,23] were entered into the study together with intake and follow up 
controls. In the final retrospective analysis, including pre-and post-conceptional 
parameters only RSA and follow up control women with consecutive pregnancy were 
included. Inclusion criteria for RSA women were a history of at least two consecutive 
idiopathic miscarriages with the same partner and a wish for pregnancy. A 
miscarriage was defined as a spontaneous pregnancy loss before 16 weeks 
menstrual age. Women were excluded in case of chromosomal rearrangement in 
either partner, Lupus coagulant, anticardiolipin antibodies, or medication used to 
treat disorders other than vitamin B6 and B12 deficiency, diabetes mellitus, 
polycystic ovarian syndrome or thyroid dysfunction. Upon intake a first blood sample
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was drawn. Subsequently, women were given folic acid supplementation (0.5 mg 
daily) and after a 2 months period a second blood sample was drawn. As intake 
controls 37 non-pregnant healthy control women with at least one successful 
pregnancy and no history of RSA were entered into the study. As follow up controls 
39 women successfully partaking in an IVF procedure were entered. These women 
also received folic acid supplementation and were followed from the pre-conceptional 
period throughout successful pregnancy. Follow up control women that miscarried 
were excluded. After pregnancy was established by urine hHcG (ICON test, 
Hybritech, Liege, Belgium) in both RSA women and follow up controls, blood 
samples were drawn at 8 and 12 weeks of menstrual age, unless miscarriage 
occurred previously. From the 43 RSA women that became pregnant, 26 carried to 
term and 17 suffered from a recurrent miscarriage. The RSA women experienced a 
median of 3 consecutive miscarriages with a range between 2 and 8, 18 out of 43 
women had a history of 2 consecutive miscarriages. The mean age of RSA women 
(31.9; 95% CI: 30.3;33.6) did not differ from intake control women (mean 32.1, 95% 
CI: 30.6;33.6) or follow up control women (mean 33.0, 95% CI: 32.0;34.1)(t-test, 
p>0.05). The Institutional Review Board of the University Hospital Nijmegen 
approved the study and all women gave written informed consent, before 
participation.
NK cell cytotoxic reactivity
From all blood samples, peripheral blood mononuclear cells (PBMC) were isolated 
by density centrifugation (Lymphoprep, Nycomed, Oslo, Norway) and stored in liquid 
nitrogen until use. NK cell reactivity was assessed using a 51Cr release bioassay. In 
short: effector cells were thawed and overnight incubated in medium containing 
RPMI1640 Dutch modification (Life Technologies, Paisley UK) supplemented with 
10% FCS (PAA, Linz Austria), 0.02 mM sodium pyruvate 100U/ml penicillin and 
100|iM streptomycin (both Life Technologies, Paisley UK). 1*106 K562 target cells 
were labelled with 3.7MBq 51Cr (Amersham, UK) for 2 hours. Then, 1*103 labelled 
target cells were added to 80 * 103, 40 * 103, 20 * 103 or 10 * 103 of effector cells 
resulting in four different Effector/Target cell ratio’s (80:1, 40:1, 20:1, 10:1). 
Incubation was for 4 hours in a humidified incubator at 37°C and 5% CO2. After 
incubation, 100|il of supernatant was harvested and radioactivity was measured 
using a y-counter (Wallac 1470 y counter, Turku, Finland). The percentage specific 
NK cell cytotoxic reactivity was determined as follows:
. sample value -  spontaneous release
/  lysis —----------------------------------------------------------
maximum release -  spontaneous release
In order to express cytotoxic reactivity independent of an arbitrarily selected E/T 
ratio, and to allow for reliable comparison between samples of distinct individuals 
tested at different moments in time, the specific lysis of the four E/T ratio’s per 
sample were conversed to Lytic Units (LU)[24]. The LU was defined as the number 
of times that an amount of effector cells, that gives rise to a specific lysis of 20%, 
was contained in 107 effector cells (LU=107/number of cells yielding 20% lysis). We 
therefore calculated the median of the logarithmic transformed specific lysis of the 4 
E/T ratio’s of each tested sample the number of cells yielding 20% specific lysis. 
Thus creating a robust method to compare different samples without 
disproportionate effects of occasional erratic data.
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Flowcytometric labelling and analysis
Cells were phenotypically analysed by a 2-step double labelling procedure. Briefly, 
cells were washed three times with FACS buffer (PBS containing 0.5% BSA) and 
labelled first with (un)conjugated specific antibody, if necessary followed by 
conjugate binding (GAM-FITC: DAKO, Glostrup, Denmark). Thereafter the cells were 
labelled with a secondary conjugated specific antibody. All incubations were for 30 
minutes and thereafter the cells were washed twice. The samples were run on a XL- 
Epics (Coulter Electronics) and 5000 or 10.000 events were collected based on live 
lymphocyte cell gating as indicated by propidium Iodide (5|ig/ml) staining. Isotype 
matched antibodies were used to define marker settings, isotype matched controls 
were usually below background staining. Data were analysed by Coulter XL-2 and/or 
WINMDI software. For analyses of NK cell (subset) numbers conjugated aCD16- 
FITC (clone DJ130c), aCD56-RPE (clone MOC-1), aCD3-FITC or aCD3-RPE (clone 
UCHT1) antibodies were used (all from Dako, Glostrup, Denmark). NK cell 
inhibiting/activating receptor expression was characterised by conjugated aCD158a- 
PE (clone EB6), aCD158b-PE (clone GL183) and unconjugated aNKG2a (clone 
Z199) antibodies (all from Immunotech, Marseille, France). Isotype matched control 
antibodies were directed against Aspergillus niger (Dako, Glostrup, Denmark).
Statistical Methods
The t-test for independent samples was used to test for statistical significance of the 
differences in the mean values of the age and NK cell parameters between, first, the 
RSA group and the intake controls and, second, the RSA group and follow up 
controls. The mean values with 95% confidence intervals (CI) are presented.
The t-test for paired samples was used to test for statistical significance of the 
differences in the mean values of age and NK cell parameters within the RSA group 
before and after folic acid supplementation. The mean values with 95% CI are 
presented.
Repeated measurement analysis adjusting for the pre-conceptional value was used 
to test for statistical significance of the differences between the RSA group and 
follow up controls in the mean NK cell parameters at 8 and 12 weeks after 
conception. The estimated means with 95%CI are presented.
Differences between the groups may be influenced by the loss of information of 
those women who miscarried. Therefore the repeated measurement analysis was 
also performed using the method of last observation carried forward (Lo Cf ). The 
LOCF method was performed at each assessment point, substituting missing values 
after miscarriage at all subsequent assessments by the last observed value after­
conception. The results of both analyses were similar and those using the LOCF 
method are presented here. It is obvious that these variables are not mutually 
independent. Therefore the P-values are presented unadjusted for analysing multiple 
variables. Note that p-values are adjusted for multiple comparisons of each variable 
(Table 2: Tukey-Kramer).
Finally, the influence of the pre-conceptional value of age and NK-cell parameters, 
separately, on the probability of miscarriage in women with RSA was analysed using 
univariate logistic regression. The crude odds ratios with 95% CI are presented. The 
dichotomized data were analysed using Fisher’s exact test.
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Pre-conceptional peripheral NK cell reactivity and cell numbers
We assessed whether in our centre pre-conceptional peripheral cytotoxic NK cell 
reactivity, NK and T cell levels in women with a history of unexplained recurrent 
spontaneous miscarriages differed from controls. Table 1 shows the estimated 
values before and during folic acid treatment for NK cell cytotoxicity (LU), and 
peripheral NK cell levels.
Table 1:The mean and 95% confidence interval (Cl) of pre-conceptional NK cell 
cytotoxicity (Lytic Units) and percentage of NK cell subsets in RSA women and
Results
folic
acid
Intake controls 
Mean (CI)
RSA 
Mean (CI)
Follow up controls 
Mean (CI)
p p p
Lytic Units before
during
445.0 (415.6;475.9) 411.0
393.1
(378.1;444.0)
(362.2;423.9) 364.5 (338.1;391.0)
- - -
% CD56pos CD3nea before
during
13.5 (10.8;16.3) .2 
.8 
3. 
5.
.0) 
.8) 
6
8
 
.4; 
.8; 
0
2
12.5 (8.8;16.2)
- - -
% CD56posCD16pos 
CD3neg
before
during
12.0 (9.6;14.4) 11.6
12.9
) 
7) 
.2 
5. 
14 
;1 
.0; 
0.1 
(9 
(1 11.7 (8.4;15.0)
- - -
% CD56posCD16nea 
CD3neg
before
during
1.4 (0.7;2.1) .4 
.4 
1
2
.2) 
.4) 
;2 
;3 
.7; 
.5; 
(0. 
(1. 1.8 (0.7;3.0)
*
% CD56posCD16nea 
/CD56posCD16pos
1___ .■ - _
before
during
0.39 (0.21;0.57) 0.25
0.55
4) 
2) 
.4 
.8 
;0. 
;0. 
6; 
8; 
.0 
.2 
0. 
0. 
(
(
0.56 (0.23;0.89)
**
t-test for independent samples; : p-value for the difference between mean value in the RSA women 
and the follow up controls, : p-value for the difference between mean value in the RSA women before 
and afterfolic acid treatment. **: p< 0.01, *: 0.01 < p < 0.05, -:p  > 0.10.
Before folic acid treatment analysis a mean LU level of 411 (95% Cl: 378.1;444.0) 
was found in RSA women, which was not significantly different from the level found 
in intake controls (mean 445.0, 95% Cl: 415.6;475.9) (p=0.126). Similarly, no 
difference was found for either CD56posCD3ne9 NK - or CD3pos T cell levels between 
RSA women before folic acid treatment and controls. ln both groups the percentage 
of cells was ~ 13% for NK cells and 68% for T cells. Analysis of subset division of NK 
cells into double CD56pos CD16pos and single CD56pos cells neither revealed a 
statistically significant difference between the groups.
During folic acid treatment NK cell levels in RSA women were compared with follow- 
up control women, successfully partaking in an IVF procedure and also receiving folic 
acid treatment. None of the parameters tested revealed a substantial difference 
between RSA women and controls. The estimated mean LU levels in the RSA and 
follow up control group were 393.1 (95% Cl: 362.2;423.9) and 364.5 (95% Cl:
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338.1;391.0), respectively (p=0.165) and the mean total NK cell levels were 15.8% 
(95% Cl: 12.8;18.8) and 12.5% (95% Cl: 8.8;16.2), respectively (p=0.169).
Effects ofpre-conceptional folic acidsupplementation in the RSA women
Since RSA women with a wish to conceive received folic acid treatment upon 
entering the clinic, we analysed whether the pre-conceptional intake of folic acid was 
associated with a subsequent change in NK cell parameters. A comparison of 
peripheral NK cell levels and activity before and during folic acid treatment within the 
RSA group (Table 1) revealed no statistically significant change in cytotoxic activity. 
LU levels were 411.0 (95% Cl: 378.1;44.0) before and 393.1 (95% Cl: 362.2;423.9) 
during treatment (p=0.185). Also, neither the total number of NK cells nor the number 
of T cells changed substantially. However, when looking at NK cell subsets, we did 
observe a significant rise in single CD56pos NK cells, from 1.4% (95% Cl: 0.7;2.2) up 
to 2.4 (95% Cl: 1.5;3.4) associated with a significant change in the ratio single 
CD56pos / double CD56pos CD16pos cells from 0.25 (95% Cl: 0.06;0.44) up to 0.55 
(95% Cl: 0.28;0.82)(p=0.008).
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Figure 1:The estimated mean NK cell cytotoxic reactivity (LU) and NK cell parameters in 
RSA women (□ ) and follow up controls ( • )  at each assesment point, using the method of 
last observation carried forward (LOCF). The vertical lines indicate the 95% confidence 
interval.
Post-conceptional peripheral NK cell reactivity and cell numbers
We were also interested in finding out whether during the first trimester of pregnancy 
in RSA women (including both women who carried to term as well as those that 
aborted) NK and T cell parameters underwent distinct changes in comparison with 
controls. Figure 1 shows the course of NK cell cytotoxicity levels and cell numbers
82
Peripheral NK cells and pregnancy
starting from pre-conceptional values up to12 weeks of menstrual age, in both RSA 
women and controls. From Figure 1 it is clear that differences between the groups 
are most outspoken at week 8 of menstrual age. To be better able to evaluate the 
differences between the groups, the estimated values as derived from the repeated 
measurements model, are depicted in Table 2. The differences were calculated for 
the overall period (column 2), and for each of the assessment points separately 
(columns 3 and 4). Adjusted for the pre-conceptional values, it appeared NK cell 
cytotoxicity (expressed as lytic units) at week 8 was significantly increased in the 
RSA group as compared to the controls (a difference of 55.2 (95% Cl: 10.6;99.8)). 
But, this difference tapered off and was almost negligible at week 12 (6.9 (95% Cl: - 
37.1;50.9).
Table 2:Estimated differences in mean NK cell parameters between RSA women 
and follow up controls during pregnancy measured at both week 8 and 12 of 
menstrual age using repeated measurement analysis adjusted for the 
preconceptional value and on the basis of last observation carried forward.__________
Mean difference (Cl) between RSAwomen and follow up Simultaneous
controls levels of
significance
Overall Week 8 week 12 menstrual 
menstrual age age
p1 p2 p3 p4
Lytic Units 31.0 (2.5;59.6) 55.2 (10.6;99.8) 6.9 (-37.1;50.9) * * **
% CD5(f°s CD3nej 4.0 (0.4;7.6) 5.4 (-0.2;11.0) 2.6 (-2.9;8.1) * **
% CD56posCD16pos 
CD3neg
4.9 (2.0;7.8) 6.4 (1.8;10.9) 3.4 (-1.1;7.9)
% CD56posCD16nej 
CD3neg
-1.0 (-1.8;-0.2) -1.0 (-2.2;0.2) -1.0 (-2.2;0.3) * **
% CD56posCD16nej 
/CD56posCD16pos
-0.55 (-0.75;-0.36) -0.65 (-1.0;-0.30) -0.45 (-0.81;-0.08) **
1 Adjusted p-value according to the method of Tukey-Kramer of the overall difference between RSA 
women and follow up control women; 2: p-value of the test for statistical significance between the 
assessment points; 3: p-value of the test for statistical significance of the group differences between 
the assessment points; 4: p-value of the test for statistical significance of the regression of the pre­
conceptional value during folic acid treatment, indicating that the pre-conceptional value significantly 
contributes to estimate the parameter at each assessment point. **: p <0.01, *: 0.01 < p < 0.05, [*]: 
0.05< p< 0.10, -: p> 0.10.
Similarly, NK cell levels in RSA women were higher during pregnancy (an overall 
difference of 4.0% (95% Cl: 0.4;7.6), mainly due to a higher level of double 
CD56posCD16pos cells. This effect was again most outspoken at week 8 of menstrual 
age (5.4% (95% Cl: -0.2;11.0)) but in this case was maintained at week 12. Levels of 
single CD56pos cells were lower in RSA women as compared with controls, both at 
weeks 8 and 12. ln combination with the higher levels of double CD56posCD16pos 
cells this resulted in a notable reduction in the ratio single CD56pos / double 
CD56posCD16pos NK cells (-0.65 (95% Cl: -1.0;-0.3)). Notably, the concomitant rise of
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NK cell cytotoxicity, increased numbers of CD16pos NK cells and decreased levels of 
single CD56pos cells fits the known characteristics of NK cell activation.
CD3pos cell numbers (including the CD3posCD56pos cells) remained unchanged during 
pregnancy (data not shown).
Risk factors for miscarriage within the RSA group
Although all RSA women had a history of miscarriages, two-third of these women 
successfully carried their next pregnancy to term. Consequently, we looked for 
parameters that could predict the pregnancy outcome in the group of RSA women. 
The effect of the following parameters, measured before pregnancy, on the 
probability of a miscarriage was studied using univariate logistic regression analysis 
in the group of RSA women with two or more spontaneous abortions: age, LU, %NK 
cells, %  double CD56posCD16pos cells, %  single CD56pos cells, ratio single CD56pos / 
double CD56posCD16pos cells, %  CD3pos cells, %  double CD3pos CD56pos cells. Of 
these parameters only age proved to be a substantial risk factor with a 37% 
increased risk of miscarriage with each additional year of age (OR=1.37; 95% Cl: 
1.07-1.92; p=0.03).
ln addition, using the data from the regression analysis, we dichotomised the data for 
the abovementioned parameters and analysed both women with two or more 
abortions and those with three or more abortions. Table 3 shows the results for the 
preconceptional values (women were on folic acid).
Table 3: Retrospective analysis of putative risk factors for subsequent miscarriage 
within RSAwomen.
Parameter cut off 
value
successful
pregnancy#
miscarriage* p-value
Lytic Units <322 4 (3) 3 (3)
>322 12 (7) 5 (3) - (-)
% CD56pos CD3nea <12.0 8 (5) 0 (0)
>12.0 7 (4) 7 (5) * ([*])
% CD56posCD16posCD3nea <20.7 12 (8) 7 (6)
>20.7 4 (2) 2 (1) - (-)
% CD56posCD16nea CD3nea <4.0 14 (8) 5 (3)
>4.0 1 (1) 2 (3) - (-)
% CD56posCD16nea /CD56posCD16pos <0.08 5 (3) 2 (1)
_ _______ ._________ -c r - , , , »  ________
>0.08 10 (6) 5 (5) - (-)
ff:Depicted are the number of RSA women with successful pregnancy or subsequent miscarriage after 
dichitomising using the depicted cut off values. Values between parenthesis are the number of RSA 
women with 3 or more subsequent miscarriages. *: 0.01 < p < 0.05, [*]: 0.05 < p < 0.10, -:p > 0.10.
Notably, using a threshold value of 12 %  [25], in non-pregnant RSA women on folic 
acid treatment a low NK cell percentage was significantly associated with a 
successful subsequent pregnancy (p=0.02; Fisher Exact test). ln fact, all of the eight 
RSA women with pre-conceptional NK cell numbers <12% had subsequent 
successful pregnancies. ln the group of women with three or more miscarriages the
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effect was similar, but due to low numbers not significant. 
parameters tested revealed a significant effect in either group.
None of the other
KIR/KAR and NKG2a expression on CD56?os cells
Both uterine and peripheral NK cells can be activated or inhibited via specific 
surface molecules. The killing inhibitory/activating receptors CD158a, CD158b and 
NKG2a are examples of such surface molecules and are thought to interact with their 
ligands, HLA-C and HLA-E (presenting processed HLA-G), respectively. These 
receptors are known to be expressed at the fetal-maternal interface. ln order to 
ascertain whether there are differences in NK cell inhibitory receptor repertoire 
between RSA women and controls, we determined the expression of CD158a, 
CD158b and NKG2a receptors on peripheral NK cells by flowcytometry (as shown in 
Figure 2). Expression was similar for all groups studied. CD158a, CD158b and 
NKG2a were expressed on approximately 20, 30 and 45% of CD56pos cells, 
respectively.
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Figure 2: Expression of CD158a and CD158b (with specificity for HLA-C molecules) and 
epression of NKG2a receptor (specific for HLA-E, complexed with amongst others 
processed HLA-G molecules) on CD56+ cells. Depicted are individual readings (•), 
means (O) and 95% confidence interval (-).
Discussion
Recently, attention has focussed on the role of uterine NK cells as mediators in 
successful implantation and placental maturation [26,27,27]. lt is thought that these 
cells exert their function through cytokine production rather than cytotoxicity. ln fact, 
the latter function should be inhibited to prevent pregnancy failure. Notwithstanding 
the fact that spontaneous miscarriage is a typically localised process, it is of great 
interest to evaluate systemic changes that precede this process, in particular for 
future diagnostic purposes. With this objective we performed a longitudinal study on
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peripheral NK cell parameters and were able to define that within the group of RSA 
women pre-conceptional CD56pos levels of less than 12% were associated with a 
successful subsequent pregnancy. ln fact this confirms previous data [17] who 
showed that high NK cell levels are associated with RSA and subsequent 
miscarriage. This held true for women with either two or more as well as for those 
with three or more spontaneous miscarriages.
Notably, before pregnancy we could not detect a significant difference in either NK 
cell cytotoxicity or numbers of double CD56posCD16pos cells between RSA women 
(grouped irrespective of the outcome of their next pregnancy) and controls, but we 
did observe a marked difference between these groups in early pregnancy. Whereas 
both cytotoxicity and NK cell numbers increased in the RSA group with advancing 
pregnancy, peaking at week 8 menstrual age, the opposite effect was found in the 
controls. The controls were women partaking in an lVF procedure, but the exact 
same trend was previously observed for other healthy pregnant women [28], 
validating our choice of controls in this respect.
ln the RSA women the ratio of single CD56pos / double CD56posCD16pos cells was 
altered in favour of the CD16 expressing cells. Since CD16, and not CD56, was 
recently characterised as a lysis receptor mediating direct cytotoxicity [29], the 
concomitant rise in levels of cytotoxic reactivity found in the RSA group was not 
surprising.
The fact that in our study pre-conceptional cytotoxic reactivity or NK cell numbers in 
RSA women could not be linked to a higher risk of miscarriage as was previously 
shown [19,25] cannot so easily be explained. As in our study, both groups used as 
definition two or more miscarriages, however differences in protocols as, for instance 
the influence of cryo-preserved versus fresh PBMC [30] cannot be excluded. ln any 
case directly after conception these parameters did reach significantly higher levels 
in RSA women as compared to controls. Together with the fact that within our group 
of RSA women pre-conceptional NK cell levels were found to be predictive of 
subsequent outcome, the observations suggest that these cells be either directly or 
indirectly involved in the process ofspontaneous abortion.
As regards the intake of folic acid, we found a positive effect of daily 
supplementation on single CD56pos cells in RSA women. This was associated with a 
slight, but not significant drop in pre-conceptional cytotoxic reactivity. Folic acid is 
capable of lowering plasma homocysteine levels [23], and a high plasma level of this 
protein is a known risk factor for reproductive disorders such as, neural tube defects, 
placental pathology, pre-eclampsia and RSA [31]. lt is not yet clear whether the 
effects of folic acid on reproductive performance are limited to the homocysteine 
pathway or are in fact more extensive. Based on our data it would be of interest to 
further elucidate the role offolic acid on NK cell function.
ln conclusion, we have found evidence for the hypothesis that in women with a 
history of recurrent spontaneous abortion low pre-conceptional peripheral NK cell 
levels are indicative for a subsequent successful pregnancy. During pregnancy, RSA 
women have markedly increased NK cell cytotoxicity, associated with a rise in double 
CD56posCD16pos cells and a concurrent drop in single CD56pos cells. Thus in RSA, 
diagnostic and therapeutic measures aimed at characterising and modulating NK cell 
activity appear promising in the future.
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Abstract
Recent studies on the MHC Class Ib derived HLA-G molecule reveals in vitro 
functions extending beyond the limitations of innate immune responses. Therefore, 
the putative in vivo immuno-modulatory effect of HLA-G might be extended to tumor 
and transplant immunology. Membrane HLA-G (mHLA-G) not only affects classical 
NK cell cytotoxicity, but also determines the faith of activated T cell populations 
through apoptosis, inhibition of allo-induced cellular immunity and the maturation of 
antigen presenting cells. Based on its putative in utero effects, we hypothesized that 
HLA-G distinctly affects T and NK cell function.
For this purpose, HLA-G1 transfected cells were co-cultured in different 
effector/stimulator ratios with peripheral blood mononuclear cells (PBMC) or purified 
T or NK cells. A high dose of mHLA-G (5.0 - 10.0 x 104 cells) inhibited the T cell 
proliferation as well as IFN-y and TNF-a production by T cells. In contrast, at an 
equivalent dose of mHLA-G both NK cell proliferation and cytokine production were 
stimulated. Notably, the effect of mHLA-G on T cells was inverted by low dose of 
mHLA-G.
Our findings imply a finely tuned modulatory effect of mHLA-G on both T and NK cell 
functions.
Introduction
The focus on HLA-G is shifting from its in utero function towards the capacity of this 
molecule to potently modulate adaptive immune responses, whereby suggesting in 
vivo immuno-modulatory properties more elaborate than initially expected from its 
putative role in pregnancy [1,2]. Indeed, recently it has been suggested that the 
success of hart graft acceptance or the control of autoreactive T cells in psoriasis is 
related the expression of HLA-G [3,4].
HLA-G exists as at least 7 different spliceforms resulting in 4 membrane (mHLA-G) 
and 3 soluble (sHLA-G) forms, with molecular weights ranging between 39 and 22 
kDa [5-7]. Whereas the in situ function of the smaller HLA-G spliceforms remains 
questionable, in vitro models reveal a potent immuno-modulatory role for both full- 
length membrane and soluble HLA-G molecules [1,2]. Early studies focused on the 
classical class I mediated cytotoxicity, involving peripheral blood mononuclear cells 
(PBMC) or purified NK cells and HLA-G expressing transfected cell lines, showing an 
inhibitory effect of membrane bound HLA-G (mHLA-G) on the cytotoxic reactivity [8­
12].
More recently, it has become evident that HLA-G has immuno-modulatory properties
91
Chapter 6
extending to T cell responses, implying application in transplantation or 
autoimmunity. An inhibitory effect of mHLA-G on the CD8 mediated antigen specific 
cytolysis by T cells was suggested [13] with distinct levels of inhibition for different 
HLA-G spliceforms [11]. Furthermore, solubilised mHLA-G seems to induce 
suppression of the allo CTL-response in dose dependent manner [14]. Studies on 
allogeneic mixed lymphocyte cultures show that mHLA-G is able to suppress the 
proliferation of CD4pos T cells [15]. Interestingly, in a similar allogeneic setting the 
CD4pos fraction was shown to produce sHLA-G [16]. Data on the in vitro function of 
sHLA-G show that sHLA-G, like the classical soluble class I molecules, is able to 
induce apoptosis in CD8pos T cells [17,18]. Both soluble and membrane HLA-G can 
affect the production of cytokines and thus shift the Th1/Th2 balance [19-21]. In 
addition, a murine HLA-G transgene model shows aberrant development of antigen 
presenting cells [22].
So far only 3 receptors with known specificity for HLA-G have been identified, being 
the killer immunoglobulin like receptor KIR4DL2 and immunoglobulin like transcript 
ILT2 and ILT4 [23-25]. Expression of KIR and ILT2 receptor has been observed in 
both NK cells and T cells [26] [27,28].
These observations show that HLA-G is a potent immune modulatory molecule that 
affects different aspects of both innate and adaptive immunity. In this study we show 
that mHLAG not merely has an inhibitory effect but modulates peripheral NK and T 
cells responses in a distinct fashion, implying a finely tuned modulatory effect for 
mHLA-G.
Materials and Methods 
PBMC and transfectant cells
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats of healthy 
blood donors by density centrifugation (Lymphoprep, Nycomed, Oslo, Norway) and 
stored in liquid nitrogen until use. The human h La  class I negative, class II positive
721.221 cell line (ATCC, Manassas, USA) was stably transfected by electroporation 
with the full length HLA-G1 transcript inserted in the pNGV1-vector [29]. Prior to the 
set up of the co-cultures HLA class II expression was confirmed by flowcytometry 
and HLA-DR and HLA-DQ mismatched PBMC were selected. In addition, 
transfectant HLA-G1 expression was confirmed by flowcytometry using the HLA-G 
specific G233 [30] and 87G [31] antibodies, typically showing numbers of HLA-G 
positive cells exceeding 95%. Cytotoxic reactivity of PBMC from different individuals 
against HLA-G1 transfected and parental cells was assessed in a 51Cr release 
bioassay resulting in an average inhibition of lysis of 50% for the HLA-G 
transfectants. Co-culture with IL-2 or IL-15 resulted in total recovery of this inhibitory 
effect of HLA-G. Cell lines were cultured in RPMI1640 Dutch modification (Life 
Technologies, Paisley, UK) supplemented with 10% fetal calf serum (PAA, Linz 
Austria), 0.02 mM sodium pyruvate 100U/ml penicillin and 100U/ml streptomycin 
(both LifeTechnologies, Paisley, UK).
Proliferation assay
At day 0, 5.104 effector cells / well (PBMC, T cells or NK cells) and 5.104 irradiated 
(200 Gy) target cells (721.221) / well were co-cultured in 96 U-bottom plates 
(Greiner, Frickenhausen, Germany). At day 3, 5, 7, and 10, 100 |il of culture 
supernatant was harvested for cytokine measurements (triplicates were pooled) and 
subsequently 0.037MBq 3H-thymidin was added per well. 3H-thymidin incorporation
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was analyzed by a gas scintillation counter (Matrix 96 beta, Canberra Packard, 
Meriden, USA).
To confirm that the inhibitory effect of mHLA-G on the proliferation of PBMC was 
specifically mediated through MHC class I molecules, these molecules were shed 
from the cell surface by acid treatment adapted from Sumitran & Möller [32]. 
Incubation of HLA-G transfected cells for 6 minutes in citric acid buffer 1% BSA (w/v) 
at pH 3.0 followed by 3 wash steps in culture medium. This resulted in a strongly 
reduced class I expression in both numbers of HLA-G (G233) positive cells (<10%) 
and mean fluorescence intensity (acid treated cells <10% of non-treated) whereas 
class II expression was unaffected (>98% positive cells and mean fluorescence 
intensity >78% of non-treated cells).
Cell sorting/analysis
NK cells and T cells were isolated from PBMC through negative selection by either 
magnetic cell sorting (MACS) or fluorescence activated cell sorting (FACS). For 
MACS isolation of NK cells the NK cell isolation kit was used according to supplier’s 
manual (Miltenyi Biotec GmbH, Germany) For MACS isolation of T cells a Dynabead 
T cell isolation kit was used according to supplier’s manual (Dynal, Oslo, Norway) For 
FACS isolation of NK cells or T cells combinations of CD3, CD14, and CD19 
antibodies (Dako, Glostrup, Denmark) or CD56 (Coulter Immunotech, Marseille, 
France) CD16, CD14 and CD19 antibodies (Dako, Glostrup, Denmark) were used, 
respectively.
Cytokine production
IFN-y, t n f  -a, IL-4 and IL-10 cytokines were measured in diluted culture 
supernatants (see proliferation assay) using a enzyme-linked immunosorbent assay 
(ELISA). ELISA plates (Greiner, Frickenhausen, Germany) and ELISA Pelikine 
Compact™ kits (CLB, Amsterdam, Netherlands) were used according to supplier’s 
manual. Extinctions were measured at 450 nm (Multiskan, Labsystems, Helsinki, 
Finland).
Results 
Membrane HLA-G modulates T and NK cell populations distinctly
To assess the effect of mHLA-G on T and NK cells, co-cultures were set up with un- 
fractioned PBMC, purified T or NK cells and HLA-G1 transfected or parental 721.221 
cells.
The time-response kinetics of PBMC co-cultured with parental 721.221 cells largely 
followed kinetics of an alloantigen induced primary T cell response, showing marked 
proliferation from day 6 through 8 (Figure 1). This response was inhibited up to 70% 
by co-culture with HLA-G1 transfected cells. Co-cultures with HLA-B44 transfected
721.221 cells did not inhibit the response. This suggests that the observed effect is 
specific for HLA-G1 transfected cells. To further confirm specificity, HLA-G1 
transfected cells were acid treated prior to co-culture. Shedding of HLA class I 
molecules from the cell surface by acid pre-treatment restored proliferation (Figure 
2). Blocking studies using anti-HLA-G monoclonal antibodies (87G, MEMG-9) yielded 
repetitively inconsistent results (data not shown).
h La -G1 transfected cells affected both NK and T cells differently. Incubation of T 
cells
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Figure 1: Membrane HLA-G inhibits the alloantigen-induced proliferation of PBMC. PBMC 
(5x104) were co-cultured in the presence of 721.221 cells, HlA-G transfected 721.221 cells 
or HLA-B44 transfected cells (5x104). The inhibition of proliferation by HLA-G transfected 
cells for different donors typically ranges between 50% and 90%. A typical experiment is 
shown. As a control PBMC were cultured in culture medium alone. Data are represented as 
the mean + SD oftriplicate values.
Figure 2:The inhibitory effect of mHLA-G on proliferation is lifted by shedding of the class I 
molecules from the transfected cell surface. Both parental 721.221 (5x104) and 721.221 
HLA-G transfected cells (5x104) were treated with acid to shed the class I molecules from 
the cell surface and co-cultured with PBMC. Co-cultures of PBMC and non-treated 721.221 
or 721.221 HLA-G transfected cells showed that there was no side effect of acid treatment 
on proliferation. Data are represented as the mean + SD oftriplicate values.
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with HLA-G1 transfected cells resulted in an inhibition of proliferation of up to 65% 
(Figure 3A). Co-cultures of T cells and HLA-G1 transfected cells showed a 70% 
reduction of IFN-y levels. The production of TNF-a by T cells was completely 
abrogated in co-cultures with HLA-G1 transfected cells. Levels of IL-4 and IL-1O 
cytokines were below the detection threshold in co-cultures with either transfected or 
parental cells (data not shown).
In contrast, incubation of NK cells with equivalent numbers of HLA-G1 transfected 
cells resulted in a 45 %  increase of proliferation. (Figure 3B). NK cells co-cultured 
with HLA-G1 transfected cells were induced to produce IFN-y, but not TNFa. NK 
cells co-cultured with parental 721.221 cells showed no detectable levels of IFN-y or 
TNFa. Levels of IL-4 and IL-10 cytokines were below the detection threshold in both 
cases (data not shown).
In conclusion, we show that mHLA-G affects the proliferation and production of 
cytokines byNK and T cells in a distinct fashion.
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Figure 3: T-cells and NK cells are modulated differently by mHLA-G. Proliferation and 
cytokine production were determined in co-cultures of purified T cells (A) or purified NK cells 
(B) and HLA-G transfected or parental 721.221 cells. Proliferation and cytokine production 
were measured on day 3, 5 and 8. Peak days of cytokine production are depicted, day 3 and 
day 8 for NK and T cells respectively. Levels of lL-4 and IL-10 produced by both nK and T 
cells were below detection threshold (not shown). Data are represented as the mean + SD of 
triplicate values.
Membrane HLA-G affects the proliferation and cytokine production of T cells in 
a dose dependent manner
Since expression of HLA-G seems tightly regulated, we addressed the question of 
whether mHLA-G as expressed at the transfectant cell surface is able to affect the 
alloresponse of PBMC in a dose dependent manner.
HLA-G1 transfected cells were able to differentially modulate the alloantigen 
induced
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Figure 4: The effect of high and low dose mHLA-G on the proliferation of PBMC. PBMC 
(5x104) of different donors were co-cultured in the presence of increasing doses of HLA-G 
transfected 721.221 cells or parental 721.221 cells. 3H-Tdr incorporation was measured on 
day 8. Two representative experiments, from 2 out of 6 different donors are shown (A and 
B). Background proliferation of PBMC, 721.221 cells or HLA-G1 transfected 721.221 alone 
did not exceed 2.5% (not shown).
proliferation of PBMC depending on the number of cells used for stimulation. (Figure 
4A and B). In donor A incubation of PBMC with doses of mHLA-G ranging between 
5.0 -10.0 x104 transfected cells resulted in an almost complete inhibition of 
proliferation. In contrast, incubation with lower doses of mHLA-G (2.5 - 5.0 x104 
transfected cells) resulted in enhanced proliferation as compared to the proliferation 
of PBMC upon co-culture with parental 721.221 cells. Apparently, PBMC from 
distinct donors are differentially affected by equivalent doses of mHLA-G (compare 
Figure 4A to 4B). PBMC from donor (A) shows full inhibition of proliferation with 
5x104 HLA-G transfected cells, whereas PBMC from donor (B) only show full 
inhibition of proliferation if co-cultured with the double number of HLA-G transfected 
cells. Individual differences in the distribution of lymphocyte subsets, density of HLA- 
G ligands on PBMC or the percentage of allo-reactive cells within the T cell pool may 
account for this discrepancy.
Inhibition upon co-culture with high numbers of transfected cells was not due to 
overcrowding or culture medium exhaustion, since incubation with 50%-reduced 
numbers of PBMC or substitution of culture medium did not affect the differential 
effect of mHLA-G (data not shown).
Membrane HLA-G also affected the production of cytokines in the co-cultures in a 
dose dependent way. Levels of IFN-y, TNF-a, IL-10 and IL-4 cytokines were 
analyzed in combinations that were either inhibited or stimulated in their proliferation 
by mHLA-G. Data show that the inhibition of proliferation of PBMC by a high dose of 
mHLA-G is paralleled by a consecutive decrease of IFN-y and TNF-a levels, whereas 
stimulation of proliferation by a low dose of mHLA-G coincides with an increase of 
these cytokines (Figure 5). Levels of IL-10 appeared increased in co-cultures with 
low stimulating dose of mHLA-G. However, levels were very low, precluding any 
clear conclusion. IL-4 levels were below detection level.
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Figure 5: The effect of mHLA-G on the cytokine production of PBMC. Culture supernatants 
were harvested from co-cultures that were either inhibited or stimulated in their proliferation 
by membrane HLA-G. In these sups IFN-y,TNF-a, IL-4 and IL-10 cytokine levels were 
determined by ELISA. IL-4 and IL-10 did not exceed background levels (not shown). Data 
are represented as the mean + SD oftriplicate values.
Having established a dose-dependent effect of HLA-G1 transfected cells on PBMC 
function, we then analyzed the effect of high-low dose mHLA-G on the proliferative 
capacity of purified T and NK cell fractions (Figure 6). Similar to un-fractionated 
PBMC, proliferation of T cells co-cultured with a high dose mHLA-G was inhibited, 
whereas a low dose mHLA-G stimulated proliferation. In contrast, proliferation of NK 
cells was stimulated upon incubation with high dose mHLA-G but any effect of low 
dose HLA-G was absent (Figure 6). Thus in PBMC, the HLA-G dose induced switch 
from inhibition to stimulation of proliferation is mainly due to its effect on T cells and 
represents a threshold-like transition rather than a dose response curve.
In conclusion, we show that mHLA-G affects the proliferation and cytokine production 
by PBMC, in particular T cells, in a dose dependent manner.
Discussion
Recently it has become evident that the HLA-G molecule not only plays a role in 
feto/maternal tolerization, but also might affect peripheral immune responses related 
to tumors and autoimmunity [4,33-35]. These functions of HLA-G are not merely the 
effect of modulation of NK cells but putatively involve a modulatory effect on T cell 
function as well [36]. In this study it was shown that HLA-G modulates T and NK cells 
distinctly. Inhibition of T cell proliferation and cytokine production and concomitant 
stimulation of NK cell proliferation and cytokines by HlA-G1 transfected cells show 
the ambivalent effect of membrane HLA-G. Furthermore, a dose dependent effect of
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Figure 6: NK and T cell populations are distinctly modulated by high and low dose of mHLA- 
G. Co-cultures of purified NK and T cell populations (from a single donor) with high and low 
dose HLA-G1 transfected or parental 721.221 cells. Data are represented as the mean + SD 
of triplicate values.
HLA-G on proliferation and cytokine production on PBMC and T cell or NK cell 
fractions was established. Taken together, an immmuno modulatory role in T cell 
function is implicated for HLA-G.
It was shown that the effect of HLA-G1 transfected cells on the alloantigen-induced 
proliferation of PBMC primarily reflects the modulation of T cells rather than NK cells. 
This implies that effects of HlA-G should be mediated via ligation with receptors 
present on T cells. In our set up with the HLA class II mismatched 721.221 cells, we 
suggest that activation of T cells is putatively mediated through recognition of the 
HLA class II peptide complex by the T cell receptor in the context of CD4. This 
concept is supported by data from Bainbridge et al. [15] suggesting that an inhibitory 
effect of HLA-G on an alloantigen induced response was directly mediated through 
CD4pos T cells, independent from CD8pos T cells and antigen presenting cells. 
Therefore, in this set up interaction of HLA class I molecules with the T cell receptor 
complex and CD8 seems less pronounced, although this pathway seems functional 
for HLA-G [37]. Taken together this suggests that alloantigen activated T cells carry
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receptors specific for HLA-G that are able to affect T cell function.
So far 3 different receptors with known specificity for HLA-G have been identified, 
being the killer immunoglobulin like receptor KIR2DL4 and immunoglobulin like 
transcript ILT2 and ILT4, the former two are putatively expressed by T cells and NK 
cells [25,26,28]. However, the possibility of the existence of as yet unidentified HLA- 
G specific receptors should be noted.
The inhibitory effect of HLA-G1 transfected cells is most likely mediated through 
expression of HLA-G although an effect of HLA-E cannot excluded. In our co­
cultures system expression of HLA-G was induced in 721.221 cells. In this setup 
processing and presentation of the leader peptide of HLA-G can induce cell surface 
expression of HLA-E [38]. This implies that in HLA-G1 transfected cells the co­
expression of HLA-E can contribute to the effects found in co-cultures with PBMC, T 
cells or NK cells. However, a study by Riteau et al. [39] shows that inhibitory effect of 
HLA-G on alloantigen induced proliferation was not affected by either co-expression 
or absence of HLA-E. In addition, it was suggested that co-expression of HLA-E in 
HLA-A2 transfected cells was not able to induce an inhibitory effect on the 
proliferation of PBMC as observed in co-cultures with HLA-G / HLA-E expressing 
cells [15]. The main issue is through which receptors on T cells an effect of HLA-E is 
mediated. HLA-E can be specifically recognized through the CD94/NKG2 receptor. 
This heterodimer CD94/NKG2 receptor is expressed by both T cells and NK cells 
[40,41]. However, the fraction ofthe T cell population that express CD94/NKG2 and 
the levels of expression are suggested to be fairly restricted as compared to NK 
cells, suggesting a prominent role in NK cell function. Stimulation of T cells through 
the interaction between CD8 and HLA-E seems hampered by its low affinity binding 
[37], although a resent study suggests that this pathway is functional [42]. The 
absence of inhibition of proliferation in co-cultures with a HLA class Ia molecule 
(HLA-B44 transfected 721.221 cells) and shedding of HLA class I molecules by acid 
treatment, shows that the effect of HLA-G1 transfected cells is a HLA class Ib 
specific effect.
In our model we suggest by the use of purified T cells a direct pathway for HLA-G1 
transfected cells on T cells. An indirect way of HLA-G to affect T cell function might 
be mediated through antigen presenting cells. This is in tune with a study by 
Horuzsko et al. [22], showing that HLA-G affects the maturation of antigen presenting 
cells in a murine h La -G transgenic model.
We show, to the best of our knowledge, for the first time that incubation of PBMC or 
T or NK cells fractions with different dose of HLA-G1 transfected cells revealed a 
dose dependent effect on proliferation and cytokine production. In addition, for T 
cells we show next to inhibition at high dose a stimulatory effect of low dose mHLA-G 
on proliferation and cytokine production. Interestingly, a study using native 
solubilised mHLA-G, suggested a dose dependent effect on allo induced T cell 
cytotoxicity and cytokine production, whereas the proliferative response was 
unaffected [14]. Therefore, to affect T cell proliferation, an additional T cell signal is 
needed next to interaction of HLA-G with its ligand, which cannot be mediated 
through solubilised mHLA-G. Notably, soluble HLA-G was shown to induce apoptosis 
in activated CD8pos T cells in a dose dependent manner [17], others have shown a 
dose dependent effect of soluble HLA-G on the production of cytokines [20]. 
However, further study is needed to gain insight in the mechanisms involved. 
Translated to the in vivo situation, i.e. allogeneic transplantation or autoimmunity, 
expression of membrane HLA-G can create new means to modulate T cell 
responses [4,36]. Therefore, to resolve this issue it should first conclusively been
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shown what factors regulate HLA-G expression in situ [43,44].
In conclusion, we show that membrane HLA-G is able to modulate an alloantigen 
induced T cell response, revealing a pathway for fine-tuning the response of allo- 
reactive T cells.
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Summary and concluding remarks
This thesis focuses on the role of the immune system in pregnancy (chapter 1). The 
field of reproductive immunology tries to elucidate mechanisms by which the 
placenta regulates the maternal immune response to the fetal allograft. Insight in this 
process is needed to clarify the etiology of pregnancy disorders like recurrent 
miscarriage and preeclampsia or the physiology of implantation in order to improve 
IVF procedures. Ultimately, knowledge on the mechanisms behind this “in vivo model 
of tolerance induction” can also have its spin off in fields like transplantation 
immunology, tumor immunology and auto-immune disease [1].
Uncovering in the 1980’s of the non-classical class I molecule HLA-G with its unique 
expression at the feto-maternal interface (coupled to the absence of HLA-A, HLA-B, 
HLA-DQ and HLA-DR) suggests a functional role in acceptance of (or induction of 
tolerance to) the fetal allograft at this immune privileged site [2]. Like preservation of 
the embryonic tissues in the uterus, other immune privileged sites (i.e. eye, brain, 
testis) share this tissue protective characteristic preventing in situ inflammatory 
reactions. Immune privilege ofthe eye putatively results from the immunomodulatory 
intra-ocular environment (i.e. TGFß-2 cytokine) on ocular antigen presenting cells 
that process ocular antigens and migrate to the spleen where they create an 
immunosuppressive microenvironment through the production of chemo attractants 
(NK T cells) and cytokines like TGFß and thrombospondin-1. The net result is the 
induction of regulatory T cells [3]. In analogy, tolerance induction at the feto-maternal 
interface during pregnancy might well be an active process constituted under the 
influence of local cytokines that are induced by a distinct pattern of MHC class I 
expression and mediated through a skewed population of immune competent cells. 
The feto-maternal interface is a fusion product of placental and decidual layers. This 
interface is not an absolute barrier as demonstrated by the exchange of cells from 
both fetal and maternal origin [4]. The uterine cavity is lined by the endometrium that 
under influence of hormones becomes receptive for successive implantation of the 
blastocyst. Upon implantation, the endometrium, then being designated as decidua, 
contains large numbers (10-15%) of lymphocytes. This lymphocyte population 
predominantly exists of NK cells (50-80%) and to a lesser extent T cells >5]. The 
proportion of NK cells decreases towards term pregnancy, whereas the number of T 
cells increase. Part of the blastocyst differentiates into distinct trophoblast cell 
populations that invade the decidua (extra-villous trophoblast) and give rise to 
formation of placental villi (villous trophoblast). More importantly, the population of 
extra-villous trophoblast cells invades the maternal spiral artery walls, thereby 
altering the vessel physiology to ensure sufficient blood flow to the inter-villous 
space. Therefore, this process of trophoblast invasion seems inherently linked to 
pregnancy outcome as indicated by the observation of shallow trophoblast invasion 
in pre-eclampsia [6].
Only this highly differentiated population of extra-villous trophoblast cells expresses 
the non-classical class I HLA-G molecule. The HLA-G molecule shows limited 
polymorphism, its expression level is high during early pregnancy and putatively 
decreases towards term [7]. Due to alternative splicing of the HLA-G primary mRNA 
transcript, different spliceforms are formed and translated into membrane bound and 
soluble HLA-G protein with molecular weights ranging between 39 and 22 kilo Dalton
[8]. That these alternative spliceforms indeed seem functional is shown by the 
presence of healthy offspring homozygous for a null allele that limits HLA-G
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expression to G2, G3 and G6 spliceforms [9]. Furthermore, next to inhibition by the 
G1 form, in vitro NK and T cell mediated cytolysis can also be inhibited by the G2, 
G3 and G4 spliceforms [10].
Nothwithstanding the mounting evidence on the involvement of some of its putative 
key players, insights in mechanisms are lacking to explain the paradigm of 
successful pregnancy [11]. In this context we have studied the expression of HLA-G 
in relation to immune competent cells in both physiological pregnancy and 
complications of pregnancy, such as miscarriage, ectopic pregnancy and 
preeclampsia. Studies of this kind are greatly hampered by the limited accessibility of 
placental material due to obvious ethical and medical restrictions on performing 
biopsies during various stages of pregnancy. Suitable animal models are not 
available as HLA-G is uniquely human and the use of an HLA-G transgenic mice 
model is restricted by differences in placental morphology [12]. Furthermore, the 
number of high affinity antibodies with known h La -G specificity is limited and 
detection ofdistinct HLA-G spliceform proteins is as yet impossible [13].
Expression of membrane HLA-G and soluble HLA-G in pathological and normal 
pregnancies
Expression of membrane HLA-G was studied in trophoblastic tissue collected from 
recurrent miscarriage and ectopic pregnancy and from chorionic villous biopsies from 
pregnancies with subsequent normal outcome performed for prenatal diagnosis 
purposes due to advanced maternal age (chapter 2). HLA-G protein expression was 
determined by immuno-histochemistry with an antibody that was generated against 
the a1-domain of HLA-G and that should therefore detect all (denatured) spliceforms 
of HLA-G [14]. Although the HLA-G protein is evidently expressed in recurrent 
miscarriage as well as in ectopic pregnancy, in recurrent miscarriage a decrease in 
HLA-G relative to the level of cytokeratin expression as compared to pregnancies 
with normal outcome was observed, suggesting a lower level of HLA-G protein 
expression. However, instead of an overall low HLA-G expression, a shift in 
spliceform distribution cannot be excluded, as we cannot rule out that the 
monoclonal antibody used might have differential affinities for distinct HLA-G 
spliceforms.
Indeed, in third trimester placental biopsies of pregnancies affected by preeclampsia 
an increase of the G5 spliceform indicative for a shift in spliceform expression was 
shown (chapter 3). Expression of HLA-G mRNA spliceforms was determined in term 
placental tissue by RT-PCR with spliceform specific primers. Expression of the G1 
mRNA, encoding for the full length membrane bound HLA-G protein, showed no 
significant differences in pregnancies affected by preeclampsia, the haemolysis 
elevated liver enzymes and low platelet count (HELLP) syndrome as well as 
normotensive control pregnancies. The G5 mRNA spliceform encodes for one of the 
soluble HLA-G molecules. Therefore, an increase in G5 is not in contradiction with 
reports that find a focal decrease of membrane bound HLA-G in preeclampsia [15­
17].
Soluble HLA-G is expressed during pregnancy in decidual tissue and in maternal 
plasma, where it putatively affects local and peripheral immune responses (i.e. 
inducing apoptosis in CD8pos T cells). Soluble HLA-G is also expressed in amniotic 
fluid, its in situ function remains unknown. It can be speculated though, that the 
presence of sHLA-G in amniotic fluid might lead to in utero oral tolerisation of the 
fetus towards the HLA-G antigen. This may be particularly relevant for female
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offspring when encountering the HLA-G molecule in adult life during pregnancy. The 
fact that HLA-G shows very little polymorphism is very helpful in this respect as it 
highly reduces the chance of an HlA-G “mismatch” and subsequent maternal allo- 
response. Another possible role for amniotic sHLA-G might be to serve as an 
antenatal signal for in utero tolerisation towards auto-antigens. Soluble HLA-G with 
its apoptotic capacity [18] might delete auto reactive T cells and therefore affect 
foetal tolerisation
Expression of soluble HLA-G was determined in amniotic fluid from pregnancies with 
offspring affected by neural tube defect and in relation with fetal gender in 
pregnancies with normal neonatal outcome (chapter 4). Soluble HLA-G was detected 
in a capture ELISA using two HLA-G specific antibodies. In mid trimester amniotic 
fluid from offspring affected by neural tube defects decreased levels of soluble HLA- 
G were demonstrated as compared to pregnancies with normal neonatal outcome. 
Whether this decrease was directly related to the etiology of neural tube defects 
remains speculative. Folate plays an important role in the pathogenesis and 
prevention of neural tube defects. Both in vivo and in vitro test show that folate 
deficiency might be associated with an impaired T cell response [19]. In pregnancies 
complicated by a neural tube defect folic acid might exert a direct effect on the highly 
proliferative trophoblast cell population via impaired DNA synthesis known for folic 
acid deficiency and subsequent decrease in soluble HLA-G concentrations. 
Interestingly, in amniotic fluid from pregnancies with normal neonatal outcome the 
soluble HLA-G content for female offspring is lower than for male offspring. This 
decrease in sHLA-G level for male versus female offspring may be due to a 
difference in maternal immune response upon recognition of sex related antigens. 
Next to recognition of fetal allogeneic major antigens, there should also be 
recognition of so-called minor histocompatibility antigens [20]. Obviously, minor 
antigen differences are prone to be enhanced for male offspring (e.g. HY antigen); 
thus evoking a more ferocious maternal immune response that needs to be counter 
balanced by the production of more sHLA-G. The apoptotic capacity of soluble HLA- 
G may delete auto reactive T cells and work as an ante-partum signal for fetal 
tolerization. The effects of amniotic fluid soluble HLA-G levels on this self/non-self 
recognition might also be of influence in adulthood and result for example in a female 
predisposition for auto immune disease [21,22].
NK cell populations and interactions with HLA-G in normal and pathological 
pregnancies
During early pregnancy NK cells are predominantly expressed in decidua and 
putatively play a key role in the interaction with HLA-G. They can be considered to 
directly affect “acceptance” of the fetal allograft. The decidual NK cells form a 
population distinct from peripheral NK cells. Decidual NK cells have the 
cD56br'9htCD16ne9 phenotype and carry large granules, their cytotoxic function seems 
secondary to the potent production of cytokines. In contrast, the major population of 
peripheral NK cells has the CD56d'mCD16pos phenotype, is highly cytotoxic, but a 
poor producer of cytokines. Some 10% of peripheral NK cells, have the 
CD56br'JhtCD16ne9 a-granular phenotype. It is suggested that the CD56br'9ht NK cells 
represent an immature subset that has the capacity to produce type 2 cytokines that 
is lost upon terminal differentiation, concomitant with IFN-y (type 1) production [23]. 
In healthy receptive endometrium and during early pregnancy the CD56br'Jht NK cell 
population is increased, and it is suggested that the presence of large numbers of
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CD56d'mCD16pos NK cells is detrimental to implantation/pregnancy. For obvious (e.g. 
diagnostic) reasons it is of interest to analyse whether this apparently tightly 
regulated balance is somehow reflected in the periphery.
In this thesis it was assessed whether peripheral NK cell parameters were linked to 
idiopathic recurrent miscarriage (chapter 5). Although preconceptional levels of 
natural killer cytotoxicity and numbers of both CD56pos and CD56posCD16pos cells 
were similar between women having previously experienced recurrent abortions and 
controls, within the group having previously experienced abortions NK cell numbers 
of less than 12% were strongly associated with a subsequent pregnancy carried to 
term. Also, in this group during early pregnancy, both cytotoxic reactivity and the 
CD56posCD16pos NK cell subset was increased in women who subsequently went on 
to have a miscarriage, whereas the CD56posCD16ne9 population decreased. The 
expression pattern of KIR on CD56pos cells was not found to be different between 
recurrent miscarriage and controls. The supplementation of folic acid prior to 
pregnancy, led to an increase of the CD56pos subset, but cytotoxic function appeared 
unaffected. Folic acid may regulate gene activity via the methylation of DNA and 
thus determine the faith of both NK cells and trophoblast cells. For example, the 
absence of class II induction by IFN-y in trophoblast cells is putatively depending on 
the hyper-methylation ofclass II promoter elements [24].
The negative association of increased NK cell numbers and cytotoxic activity with 
successful pregnancy is in tune with our immuno-histochemical data on decidual NK 
cells (chapter 2). In normal pregnancy the major part of NK cells strongly express the 
CD56 antigen and show no expression of c D16. Furthermore, these NK cells seem 
to change upon contact with HLA-G expressing trophoblasts, entering a blast like 
state that seems to be followed by the formation of apoptotic bodies and cell death. 
This is in tune with reports that describe expression of Fas and induction of 
apoptosis in CD45pos decidual leukocytes [25,26]. In contrast, in recurrent 
miscarriage tissue a sustained NK cell marker expression of both CD56 and CD16 
was paralleled by a decreased expression of h La -G. No morphological changes 
from the blast-like stage onwards were apparent. Finally, in ectopic pregnancies 
HLA-G expression in the absence of decidual NK cells was associated with a 
disturbed trophoblast differentiation. We propose that the process of programmed 
cell death is rudimentary to placentation and under control of HLA-G expression. 
Finally, the interaction between membrane-bound HLA-G (mHLA-G) expressing cells 
and immune competent cells was studied in an in vitro model (chapter 6). The
721.221 B-cell lymphoma cell line was transfected with a full length HLA-G cDNA. 
These mHLA-G expressing cells were incubated with peripheral blood mononuclear 
cells or purified sub-fractions of peripheral blood mononuclear cells. Proliferation and 
cytokine levels were assessed by 3H-Thymidine incorporation and ELISA 
respectively. First of all, it became apparent that mHLA-G affects NK and T cells in 
distinct fashion. Whereas large numbers of mHLA-G transfected cells stimulated NK 
cell proliferation and cytokine production, T cells were inhibited. Notably, the effect 
on T cells proved to be more complex as high and low dose mHLA-G induced 
respectively inhibitory and
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Figure 1. Interactions of HLA-G with uterine immune competent cells
Several non-exclusive pathways for the interaction of HLA-G with uterine immune competent 
cells can be proposed (A, B, C). The net result will be determined by levels of expression 
and localization. In pathway (A) HLA-G expressed by trophoblast cells results in NK cell 
activation through a HLA-G specific receptor. NK cells react by producing cytokines that 
create an environment suited for the regulation of trophoblast invasion. (B) Represents a 
pathway in which HLA-G directly modulates APC function through a HLA-G specific receptor. 
The APC may become activated through signals related to the process of 
nidation/implantation or pathogens. Interaction with HLA-G creates an immunoregulatory 
micro-environment. Upon ligation these APC may not only produce regulatory cytokines but 
also chemoattractants that will further shape the cellular composition of the environment. 
The net result will be a set of regulatory T cells that can induce local and/or peripheral 
tolerance if needed. Pathway (C) represents a way, via co-receptor ligation, to directly 
enhance T cell apoptosis in those cells that have become activated upon contact with 
pathogens, in order to prevent the immune response from causing severe tissue damage.
G: HLA-G, sG: soluble HLA-G, Tcr com: complex of T cell receptor and MHC with peptide, 
cos: costimulation signal, Ag:pathogen derived signal
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stimulatory effects on both T cell proliferation and cytokine production. The observed 
switch from inhibitory to stimulatory effect by membrane bound HLA-G is a threshold­
like transition rather than a dose response curve. Interestingly, peripheral blood 
mononuclear cells from different donors have distinct thresholds. This implicates that 
the immuno-modulatory effect of mHLA-G is not merely based on expression or non­
expression, but a delicate balance between the level of HLA-G expression and 
numbers of effector cells/ligand density. Translated to the in vivo situation in the 
placenta, a small decrease rather than abolishment of trophoblastic HLA-G 
expression as observed in recurrent miscarriage (chapter 2) might shift the balance 
towards a state of T cell activation and hence direct loss of pregnancy. In contrast, 
preeclamptic placentas are focally devoid of membrane bound HLA-G, leading to 
focal activation of the decidual T cell population resulting in pre-term birth rather than 
direct loss of pregnancy. This is in tune with data that show an increase of the 
CD8pos T cell fraction in preeclampsia [27].
We confirmed the finding that mHLA-G inhibits NK cell cytotoxicity, but this is 
obviously not its major function and very likely of minor importance in placental 
tissues.
From our results, it is clear that mHLA-G has immunomodulatory potential, not only 
in the placenta, but also in the periphery. Already, it was shown that membrane HLA- 
G suppressed the class II induced allo-response of CD4pos T cells [28]. In addition, 
the presence of both soluble and membrane bound HLA-G (whether of amniotic or 
endogenous origin) in thymus epithelial cells suggest a role for HLA-G in negative 
selection ofT cells [29,30].
The ability of HLA-G to prolong skin graft survival by affecting the maturation of 
antigen presenting cells (APC) in a HLA-G transgenic mouse model shows an 
indirect way for HLA-G to influence T cell responses [31]. Notably, one of the current 
concepts for induction of tolerance as proposed by Matzinger in the “danger model” 
focuses on the mode of antigen presentation [32]. In this concept, the induction of 
tolerance relies on the activation of T cells through the T cell receptor complex 
(signal 1) in the absence of co-stimulation (signal 2), this as a result of presentation 
of antigen by immature dendritic cells or non-professional APC.
Thus, whereas in healthy pregnancy HLA-G may regulate and dampen T cell 
responses, it becomes feasible that a first trimester decrease in HLA-G leads to a 
population of maternal/maternal antigen presenting cells that evoke more potent 
(detrimental?) second and third trimester T cell responses.
Taken together, multiple pathways can be suggested that relate feto-maternal 
tolerance to the interaction between HLA-G and immune competent cells as 
proposed in Figure 1.
In conclusion, understanding the expression of HLA-G at the feto-maternal interface 
and its interactions with decidual cells has deepened insight in implantation, 
placentation and the etiology of various related disorders. This may bring the 
development of therapies a small step closer. Furthermore, the immuno-modulatory 
properties of HLA-G might be well applicable in the field of transplantation 
immunology and autoimmune disease.
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Samenvatting
Het humaan immuunsysteem is in staat om ziekteverwekkers te herkennen aan 
pathogeen specifieke moleculen, de zogenaamde antigenen. Voor het uit de 
wegruimen van allerhande gevaren heeft het immuunsysteem voor dit doel een 
grootte verscheidenheid aan celtypen ter beschikking elk met zijn specifieke functie. 
Zo zal in geval van een lokale infectie het bacteriële antigeen verwerkt worden door 
de antigeenpresenterende cel die het antigeen verwerkt en presenteert in de 
lymfknoop aan helper cellen die op hun beurt effector cellen (o.a. T cellen) 
aanzwengelen die vervolgens de plaats van infectie infiltreren en de indringer 
opruimen. Er zijn in het lichaam een aantal compartimenten waar een dergelijke 
ontstekings reactie desastreus zou zijn voor het weefsel en de daaraan gerelateerde 
functie. Vandaar dat organen als de hersenen en ogen gekenmerkt worden door een 
aangepaste immuun respons, het zijn zogenaamde "immune priveleged sites".
Een bijzondere immune priveleged site vormt tijdens de zwangerschap de 
baarmoeder die de aanwezigheid van de vrucht tolereert. Het bijzondere aan de 
zwangerschap is dat het kind genetisch gezien afwijkt van de moeder, het bestaat 
voor de helft uit nieuwe genen van de vader en bovendien zullen bepaalde 
moederlijke kenmerken missen. Een situatie die als je die vergelijkt met bijvoorbeeld 
een orgaan transplantatie alleen te handhaven is met behulp van immuun 
suppressieve geneesmiddelen. Logisch gevolg van dit genetische verschil tussen 
moeder en kind is dat de cellen van het kind andere antigenen zullen dragen dan de 
cellen van de moeder en in die zin als vreemd herkend kunnen worden door het 
moederlijk immuun systeem. Van groot belang hierbij zijn de humane leukocyten 
antigenen (HLA) die op vrijwel alle lichaamscellen voorkomen (HLA klasse I) en op 
de cellen van het immuunsysteem (HLA klasse II).
Tijdens de zwangerschap nestelt de ontwikkelende vrucht zich in het baarmoeder 
slijmvlies waarmee er direct contact ontstaat tussen de weefsels van de moeder 
(baarmoeder slijmvlies en bloed) en de vrucht (placenta). Aldus ontstaat er een 
grensvlak tussen moeder en kind dat bestaat uit placenta vlokken waartussen het 
moederlijk bloed vrij kan stromen. Kenmerk van deze vlokken is dat de buitenste 
laag ervan uit trofoblast cellen bestaat die op de plaatsen waar ze moederlijk weefsel 
raken en er mee vergroeien het klasse I molecuul HLA-G op hun oppervlak hebben. 
HLA-G komt onder normale omstandigheden niet op lichaamscellen voor. Bovendien 
ontbreken op trofoblast cellen twee van de drie typen klasse I moleculen die je 
normaal op lichaamscellen wel vindt. HLA-G is dus een bijzonder HLA molecuul op 
een bijzondere plaats en is uniek voor de mens. Bovendien, de genetische variatie 
van het HLA-G molecuul is zeer beperkt wat biologisch gezien een aanwijzing kan 
zijn dat veranderingen in HLA-G ongunstig zijn en verdwijnen door negatieve 
selectie. Zoals gezegd vergroeien de trofoblast cellen met het baarmoeder slijmvlies 
en vormen zo de decidua. In het moederlijke deel van de decidua vind je vergaande 
aanpassingen qua populaties immuun competente cellen. Vroeg in de zwangerschap 
bestaat deze populatie cellen voornamelijk uit natural killer (NK) cellen en hebben T 
cellen slechts een klein aandeel. NK cellen zijn instaat om cellen die geen HLA 
klasse I op hun oppervlak hebben (bv. een lichaams cel die geïnfecteerd is door een 
virus kan zijn klasse I verliezen). te doden en hebben receptoren waarmee ze 
verschillende klasse I moleculen kunnen herkennen.
Aldus kan men veronderstellen dat HLA-G tijdens de zwangerschap een belangrijke 
regulerende rol kan spelen in de placentatie en uiteindelijk het 9 maanden gedogen 
van de “vreemdeling”. In dit proefschrift wordt ingegaan op de interacties die kunnen
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plaatsvinden tussen HLA-G en immuun competente cellen als NK en T cellen. 
Daarbij wordt de situatie waarbij er iets fout gaat tijdens de zwangerschap zoals een 
spontane miskraam, buitenbaarmoederlijke zwangerschap of zwangerschaps 
vergiftiging (preeclampsie, HELLP syndroom) vergeleken met een normale 
zwangerschap.
Het onderzoek kan ruwweg verdeeld worden in 2 delen. Ten eerste, de expressie 
van het membraan HLA-G eiwit en de verschillende afsplits varianten (spliceforms) in 
placenta weefsel en de expressie van de oplosbare HLA-G vorm in vruchtwater 
(amniotic fluid). Kortweg de expressie van HLA-G. Ten tweede, de mogelijke 
interacties die HLA-G kan aangaan met de immuun competent cellen in de 
baarmoeder, de mogelijke afspiegeling daarvan in de NK en T cel populaties van 
perifeer bloed en in een in vitro model met cellen die op een kunstmatige manier 
HLA-G tot expressie brengen. Kortweg de interacties van HLA-G met 
immuuncompetente cellen.
De expressie van HLA-G
De expressie van het HLA-G molecuul zoals die in situ voorkomt op het oppervlak 
van de celmembraan van trofoblast cellen is bepaald in normaal placenta weefsel, 
placentaweefsel verkregen van herhaalde spontane miskramen en 
buitenbaarmoederlijke zwangerschappen (hoofdstuk 2). In het placenta weefsel van 
spontane herhaalde miskramen laten we zien dat HLA-G verlaagd tot expressie komt 
ten opzichte van een normale zwangerschap. In buitenbaarmoederlijke 
zwangerschappen was de expressie van HLA-G in de afwezigheid van deciduale NK 
cellen geassocieerd met een verstoorde differentiatie van de trofoblast cellen. Hieruit 
kunnen we (voorzichtig) concluderen dat in de genoemde pathologische 
zwangerschappen het fenotype van de trofoblast cellen afwijkend is.
De expressie van HLA-G word gekenmerkt door de aanwezigheid van alternative 
spliceforms. Elk HLA-G eiwit bestaat uit een aantal stukjes (domeinen) die achter 
elkaar gelegd het complete molecuul vormen. In het proces van alternative splicing 
worden bepaalde delen van de afgeschreven DNA code afgesplitst zodat na 
vertaling van deze kortere code in de bouwstenen van het eiwit, het molecuul bv. in 
plaats van 3 domeinen opeens nog maar 2 domeinen heeft (figuur 2 hoofdstuk 1). 
Het bestuderen van de HLA-G spliceforms in hoofdstuk 3 laat zien dat in 
zwangerschappen met preeclampsie de HLA-G G5 spliceform meer frequent 
voorkomt (met eenzelfde niet significante tendens voor de G5 kwantiteit) dan in 
gezonde zwangerschappen en zwangerschappen met het syndroom hemolysis, 
elevated liver enzymes and low platelet count (HELLP).
Tenslotte het bestuderen van het HLA-G G5 eiwit in vruchtwater (hoofdstuk 4). De 
G5 spliceform mist het transmembraan domein waardoor het bijbehorende G5 eiwit 
oplosbaar is. Dit soluble HLA-G (sHLA-G) wordt afgescheiden in het vruchtwater en 
over de functie hiervan kan alleen gespeculeerd worden. Met behulp van een HLA-G 
specifieke ELISA werd de hoeveelheid sHLA-G bepaald in vruchtwater van normale 
zwangerschappen en zwangerschappen waarvan het kind een neuraal buis defect 
heeft. De hoeveelheid sHLA-G was in de zwangerschappen met neurale 
buisdefecten significant lager dan in vroege en late vruchtwater monsters van 
gezonde zwangerschappen. Dit zou mogelijk een effect kunnen zijn van een 
verminderde trofoblast deling of differentiatie als gevolg van een foliumzuur gebrek, 
(= een van risicofactoren voor een neuralebuis defecten). Bij het opdelen van de 
vruchtwater monsters op grond van geslacht van de vrucht bleek dat mannelijke
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nakomelingen meer sHLA-G produceren dan vrouwelijke nakomelingen. Een 
mogelijke verklaring hiervoor kan gezocht worden in een verschil in minor antigenen, 
een mannelijke foetus verschilt meer van zijn moeder dan een vrouwelijke 
nakomeling.
De interacties van HLA-G met immuuncompetente cellen.
Placenta weefsel van normale zwangerschappen en herhaalde spontane miskramen 
is bestudeerd om de interactie tussen HLA-G expressie en deciduale NK cellen vast 
te stellen (hoofdstuk 2). Hiertoe zijn op verschillende plaatsen in de decidua de 
morfologie van de trofoblast cellen in relatie tot de NK cellen bepaald. Het contact 
met HLA-G doet het fenotype van de NK cel veranderen van een geactiveerd (blast 
like) type naar een vorm die vergelijkbaar is met geprogrammeerde cel dood 
(apoptotic bodies). Deze overgang is in placenta weefsel van herhaalde spontane 
miskramen niet aanwezig, bovendien wijkt het fenotype van de aanwezige NK cellen 
duidelijk af. De afwezigheid van deciduale NK cellen in buitenbaarmoederlijke 
zwangerschappen lijken gerelateerd aan een verstoorde trofoblast differentiatie.
De oorsprong van deciduale NK cellen is onduidelijk, mogelijk is het een unieke 
populatie afgeleid uit het beenmerg maar er bestaat ook de mogelijkheid dat deze 
cellen zijn afgeleid van de perifere bloed NK cellen. Mede door de goede 
doorstroming van de haemochoriale placenta met bloed lijkt het redelijk om aan te 
nemen dat elke zwangerschap zijn effect heeft op de perifere NK cel aantallen en 
functie. In hoofdstuk 5 zijn voor dit doel de functie en het fenotype van perifere NK 
cellen van vrouwen met een voorgeschiedenis van herhaalde spontane miskramen 
voor en tijdens een zwangerschap vergeleken met controle vrouwen. Voor aanvang 
van een zwangerschap zijn cytotoxiciteit en NK cel fenotype voor beide groepen 
gelijk. Maar binnen de groep met herhaalde miskramen zit een groep met lage NK 
cel aantallen die een betere kans lijken te hebben op een voldragen zwangerschap. 
Gedurende de vroege zwangerschap zijn de cytotoxiciteit en het aantal NK cellen 
met het CD16CD56 dubbel positieve fenotype verhoogd in de vrouwen met 
herhaalde miskramen. De aantallen CD56 enkel positieve cellen waren verlaagd wat 
in combinatie met het effect van foliumzuur toediening (geeft een toename van deze 
populatie) lijkt te suggereren dat de aantallen CD56 enkel positieve cellen iets zegen 
over het verloop van een zwangerschap.
Tenslotte laten we in een in vitro model zien dat HLA-G dat op het oppervlak van een 
cel tot expressie komt instaat is om de intensiteit van een immuun respons te 
moduleren en dat daarbij de NK en T cel functie op verschillende manieren worden 
beïnvloed (hoofdstuk 6). Voor dit doel werden witte bloed cellen (PBMC) in 
verschillende ratios samen met HLA-G getransfecteerde cellen gekweekt. De PBMC 
werden zo gekozen dat ze verschillen van HLA klasse II ten opzicht van de HLA-G 
transfectant. Dit verschil wordt herkend en zorgt ervoor dat de PBMC geactiveerd 
worden en gaan delen. Het blijkt nu dat de aanwezigheid van veel HLA-G (ten 
opzichte van de niet getransfecteerde “kale” cellen) instaat is om de T cel respons 
qua proliferatie en cytokine productie (TNF-a en IFN-y) te remmen. Terwijl eenzelfde 
dosis HLA-G NK cel proliferatie en cytokine productie activeert. Voor T cellen zagen 
we bovendien dat een lage dosis HLA-G het effect omkeert. Een en ander geeft aan 
dat HLA-G instaat is om T en NK cel responsen op een subtiele manier te reguleren 
zodat naast een rol in de zwangerschap, HLA-G ook van betekenis kan zijn voor het 
moduleren van T cellen in transplantaties en autoimuunziektes.
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Samenvattend kunnen we zeggen dat we door het bestuderen van 
zwangerschapsafwijkingen aanwijzingen hebben gevonden voor een verstoorde 
expressie van HLA-G en de daaraan gerelateerde interactie met NK cellen. Het gaat 
hierbij niet zozeer om een alles of niets principe maar om de subtiele wijze waarop 
HLA-G door hoeveelheid of spliceform in staat is om NK cel en bovendien T cel 
functies te moduleren. Dit laatste vormt ook een mogelijkheid voor de toepassing van 
HLA-G binnen de setting van transplantatie en autoimuunziekte
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